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ABSTRACT
ACCELEROMETER-DETERMINED PHYSICAL BEHAVIOR METRICS
AND THEIR ASSOCIATIONS WITH SARCOPENIA
AMONG OLDEST-OLD ADULTS
SEPTEMBER 2021
ERIC M. EBERL, B.S., UNIVERSITY OF VIENNA
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Amanda Paluch

INTRODUCTION: Sarcopenia is a loss of muscle function and muscle mass which
frequently occurs among the oldest-old adult population (aged 85+ years). The analysis
of accelerometer-determined physical behavior volumes and patterns of oldest-old adults
might provide novel insights into the associations with sarcopenia and its components.
METHODS: A total of 145 participants in the primary sample and 87 participants in the
subsample with a mean age of 88.2 (2.5) years from the Health, Aging, and Body
Composition study cohort provided cross-sectional data of handgrip strength,
appendicular lean mass, gait speed, and accelerometry. Probable, confirmed, and severe
sarcopenia were assessed based on the revised definition of the European Working Group
on Sarcopenia in Older People 2. Binomial logistic and multivariate linear regression
models as well as dose-response analyses were applied and adjusted for demographics,
accelerometer wear time, lifestyle factors, and chronic health conditions. RESULTS:
Oldest-old adults with higher total volumes of moderate to vigorous physical activity
(MVPA) (OR=0.74, 95% CI 0.62 to 0.89) showed a lower likelihood for a probable
sarcopenic condition in the primary sample. Likewise, patterns of higher accumulated
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time spent in MVPA bouts of less than 10 minutes (OR=0.78, 95% CI 0.64 to 0.95) and
MVPA bouts of at least 10 minutes (OR=0.78, 95% CI 0.63 to 0.98) were also related
with lower odds of probable sarcopenia. A 2.1 times (95% CI 1.01 to 4.35) higher
likelihood for confirmed sarcopenia was observed among participants who spent 60
minutes more per day in sedentary behavior (SB). Furthermore, 2.9 times (95% CI 1.05
to 8.02) greater odds of severe sarcopenia were identified following each 0.1 higher
active-to-sedentary transition probability (ASTP). Focusing on individual sarcopenic
components, higher total activity counts, higher MVPA, higher light intensity physical
activity (LIPA), lower SB, and lower ASTP were related with better gait speed.
CONCLUSION: The total volume of MVPA, whether accumulated in short sporadic
bouts or prolonged bouts, was associated with lower odds of probable sarcopenia. Higher
LIPA, lower SB, and a less fragmented activity pattern might also be related with a lower
likelihood of sarcopenia status and better physical performance among oldest-old adults.
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CHAPTER 1
INTRODUCTION

1.1 Background
Steady age-related decreases in muscle strength, muscle mass, and various
physical performance measures occur simultaneously.1 This progressive and generalized
loss of muscle function and mass is recognized as sarcopenia which is associated with
diminished functional ability, poor quality of life, greater fall-related injuries, more
frailty, and increased all-cause mortality among older adults.2–4 Sarcopenia affects more
than 50 million people today and will impair more than 200 million people in the
upcoming 40 years.5 In 2014, the global economic burden was estimated at USD $40.4
billion from this skeletal muscle disorder.6
The prevalence of sarcopenia and the related economic burden are expected to
rise substantially in the foreseeable future due to the rapid global increase in the number
of people aged 65 and older.1 In this context, the oldest-old adult population (aged 80-85
years and older) demonstrate the highest growth rate which is anticipated to expand
threefold between 2015 and 2050.7 This increasing proportion of older individuals can be
explained by improved living conditions and advancing medical care.3
The modifiable characteristics of physical behavior may include huge
opportunities to reduce the prevalence of sarcopenia in the community. Consequently, the
purpose of this thesis is to evaluate the associations of various physical behavior metrics
with sarcopenia and its components among oldest-old adults.
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1.2 Past and Present Definition of Sarcopenia
The term sarcopenia was coined by Rosenberg in 1988 by combining the Greek
words “sarx” which means “flesh” and “penia” which means “deficiency” to describe the
paucity of muscle tissue often observed in older adults.8 Based on this definition,
Baumgartner et al.9 developed the first epidemiological approach in 1998 to estimate the
prevalence of sarcopenia by the application of an anthropometric equation in which the
appendicular skeletal muscle mass was computed and evaluated. Soon after, researchers
ascertained that muscle quantity alone was not pivotal as a parameter of adverse events
and poor health outcomes.10 In 2010, the initial sarcopenia definition on the basis of low
muscle mass was extended by adding muscle strength and physical performance.10 This
move imposed by the European Working Group on Sarcopenia in Older People
(EWGSOP) in 2010 was supported within the field of geriatrics.11 Just 28 years after its
first terminological appearance, sarcopenia was formally recognized as a muscle disease
by the World Health Organization in 2016 with its own International Classification of
Disease, Tenth Revision, Clinical Modification code.12
Between then and now, the interest on sarcopenia has exponentially grown in the
scientific community.8 Classifying this geriatric condition as a disease has allowed
physicians to run diagnostics and researchers to investigate an officially accepted health
outcome.13 After defining sarcopenia by measures of muscle strength, muscle mass, and
physical performance in 2010,10 several other definitions, namely the International
Working Group on Sarcopenia in 2011,14 the Asian Working Group for Sarcopenia
(AWGS) in 2014 and its updated version in 2019,15,16 the Foundation for the National
Institutes of Health (FNIH) in 2014,17 and the revised definition of the European Working
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Group on Sarcopenia in Older People 2 (EWGSOP2) in 2019,18 were developed with
differences in their methodological approach.19 These operational dissimilarities are also
based on racial and ethnic differences in body composition and grip strength.20 As a
consequence, epidemiological prevalence studies vary substantially and depend on the
definition used.20 For instance, lower estimates of sarcopenia are usually stated in studies
which included measures of muscle function or physical performance in addition to
muscle mass.21 Likewise, differences in participant age, applied muscle mass cut points,
and the utilization of dual-energy X-ray absorptiometry (DXA) versus bioelectrical
impedance analysis (BIA) may cause substantial study outcome deviations.21 This highly
diverse application of definitions results in diagnosis rates of 1-29% in communitydwelling populations and of 14-33% among residents living in long-term care facilities.19
Another systematic review and meta-analysis found that the prevalence of sarcopenia was
between 24-40% for single measure definitions and 10-19% by employing combined
definitions.21
At this point, the most used and cited definition is the one presented by the
EWGSOP.10 Members of the EWGSOP revised their definition of sarcopenia and created
the EWGSOP2 a few years later.18 Disparities between the EWGSOP and the modified
EWGSOP2 are obvious due to alterations of cut-off values for determining low muscle
strength and low muscle mass measures.22 These changes have shown substantial
deviations in the prevalence rate of investigated populations.22 Nevertheless, EWGSOP2
is the only definition endorsed and supported by a range of international scientific
societies such as the AWGS, the European Geriatric Medicine Society, the European
Society for Clinical Nutrition and Metabolism, the European Society for Clinical and
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Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases,
International Osteoporosis Foundation, and International Association of Gerontology and
Geriatrics European Region for research and clinical practice.18
Table 1: EWGSOP2 sarcopenia cut-off values applied in our analyses
Test

Cut-off points
for men

Measurement tool

Cut-off points
for women

EWGSOP2 sarcopenia cut-off points for low muscle strength
Grip strength

Isometric handheld
dynamometer

<27 kg

<16 kg

<20 kg

<15 kg

EWGSOP2 sarcopenia cut-off points for low muscle mass
Appendicular lean mass

DXA

EWGSOP2 sarcopenia cut-off points for low physical performance
Gait speed

20-meter course

≤0.8 m/s

The definition of EWGSOP2, which will be applied in our study, identifies
probable, confirmed, or severe sarcopenia. In this regard, the detection of low muscle
strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men
and <16 kg for women) predicts a probable sarcopenia diagnosis.18 This diagnosis can be
confirmed after the observation of low muscle mass by using body composition measures
(i.e., appendicular lean mass: <20 kg for men and <15 kg for women).18 Furthermore, low
physical performance measures, which can be assessed by a variety of tests (i.e., gait
speed: ≤0.8 m/s), provide information on the severity of sarcopenia.18 A severe
sarcopenia diagnosis will be determined when all three sarcopenia-relevant indicators,
including muscle strength, muscle mass, and physical performance, show measures
below the specified cut-off points.18 All sarcopenic parameters and their cut-off values
are illustrated in Table 1.
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1.3 Muscle Strength and Muscle Mass Change across the Lifespan
A considerable amount of evidence regarding the variation of muscle strength and
muscle mass across a lifetime in the current literature is available, showing both variables
start to decline at about the fourth decade with heterogenous changes in time and
magnitude.23
Muscle Strength: As illustrated by Dodds et al.24, normative data from twelve
British studies of grip strength across the life course suggests that grip strength increases
in youth and young adulthood with a peak reached in early adulthood (up to ~40 years of
age).24 Strength in men and women may develop at a similar pace until adolescence.24
This phase is followed by a more pronounced and rapid strength gain to a higher peak
median in males compared to their female counterparts.24 The muscle strength then
steadily declines from midlife onwards in both sexes with an annual decrease of 1.5%
and an even more accelerated reduction of around 3% per year after the age of 60.24,25 By
age 80, the prevalence of weak grip strength is approximately 23% in males and 27% in
females.24
Muscle Mass: Similarly, the decline in skeletal muscle mass starts dwindling in
the third or fourth decade of life.19 Researchers estimate that approximately 20% of
muscle mass can be lost by the age of 70 years.26 While men usually show higher muscle
mass accumulations over time, they also suffer greater losses of muscle mass in later
adulthood and old age.25 Overall, after the age of 35 years, healthy men and women can
expect a loss in muscle mass of around 1-2% per year.27
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Figure 1: Disproportionate decline of leg muscle strength and leg muscle mass across the
life course. Figure adopted from Ferrucci et al.23.

With advancing age, there is an obvious tendency of disassociation between
changes in muscle strength and muscle mass (Figure 1).23 Findings of a longitudinal
study indicate that even well-functioning older men and women revealed a 3-fold greater
loss in muscle strength than in muscle mass over the course of 3 years of follow-up.28
Several other studies have already confirmed the hypothesis that the decrease in muscle
strength is much greater than the decline in muscle mass.2,23,24,29 As a consequence,
muscle strength has been considered as the key characteristic to diagnose sarcopenia.18
Muscle power, which is specified as the product of force and velocity of muscle
contraction, has shown an earlier and more drastic decline with aging compared to
muscle strength and muscle mass.29,30 In this context, muscle power has been identified
as a better predictor of functional performance measures than other sarcopenic
parameters among older adults.30 However, the demand of clinical settings with
expensive tools, the necessity of a time-consuming training for clinicians and subjects,
and the lack of standardized protocols to define low muscle power were stated as the
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main barriers to consider this metric as an assessment instrument in sarcopenia
research.31 Consequently, muscle power has been largely disregarded in previous muscle
health-related investigations.31 There is a growing interest in the field of geriatrics to
create valid muscle power measurements with better applicability in research,32,33 which
would provide the opportunity for a standardized protocol with more reliable cut-off
points to diagnose sarcopenia.

1.4 Contributing Causes of Sarcopenia and the Relevance of Physical Behavior
According to the definition imposed by EWGSOP2, the combination of low
muscle strength and mass is used to diagnose sarcopenia in clinical practice.18 This state
of skeletal muscle failure or insufficiency may occur due to a chronic degradation of
muscle strength and muscle mass with time or with sudden disease/immobility.2 Skeletal
muscle deterioration with aging is attributed to a combination of primary and secondary
factors.2 Primary sarcopenia is specified as a progressive loss of muscle quantity and
quality with advancing age when no other cause is evident.2 In this context, age-related
dysfunctions of the mitochondria, the satellite cells, and the neuromuscular system are
associated with primary sarcopenia.34 Steady decreases in hormone concentrations such
as growth hormone, testosterone, thyroid hormone and insulin-like growth factor may
also contribute to the reduction of muscle mass and strength during aging.35 Higher levels
of pro-inflammatory cytokines, including tumor necrosis factor alpha and interleukin-6,
produce catabolic signals which can diminish muscle conditions.35 Secondary aging, on
the other hand, is influenced by lifestyle factors, environmental influences, or diseases.36
Nutritional-, inactivity-, disease-, and iatrogenic-related health issues are stated as the
most frequent underlying causes of secondary sarcopenia.2 The differentiation between
7

primary and secondary sarcopenia is crucial due to therapy planning.5 By knowing and
detecting the course of these two sarcopenic manifestations, early treatment of underlying
secondary sarcopenia can prevent additional wasting of muscle quality and quantity
which further helps to avoid other health complications.5
Soon after reaching the peak of muscle mass in early adulthood, the primary agerelated loss of muscle mass indicates a continuous linear decline.37 On the contrary,
muscle wasting originated from secondary sarcopenia causes a non-linear decline with
greater progressive decreases.37 For instance, as part of a cachexic syndrome, cancers of
advanced stage can lead to an exponential muscle loss of up to 15% per 100 days which
is equivalent to approximately 30 years of aging.37 Even more pronounced are the
changes of muscle strength and mass produced by limb immobilization.38 In this regard,
the disuse of leg muscles for the duration of 4 to 7 days can lead to a 2-6% reduction of
muscle mass and an 8-22% decrease of muscle strength in young as well as older adults.38
Malnutrition is also stated as an essential underlying culprit for the development of
sarcopenia. Older adults commonly show a diminished intake of vital proteins which are
essential for a well-functioning muscle metabolism.25 This protein-energy malnutrition
negatively affects muscle functions.25 Study results of a four-year follow-up study
suggest an almost four times higher risk of acquiring sarcopenia during a malnutritional
state.39
Low physical activity (PA) levels are also stated as a main contributor for the
development of sarcopenia.13,40,41 Reductions in the overall number of steps per day
(from 6,000 – 10,000 steps per day to less than 1,000 – 1,500 steps per day) can promote
a progressive depletion of muscle strength and mass.42,43 High volumes of sedentary
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behavior (SB), on the other hand, might accelerate the loss of muscle quality and quantity
among older adults.44 Previous research has demonstrated that self-reported prolonged
sitting time is associated with higher odds of sarcopenia in older adults regardless of the
total time spent in higher PA intensity categories.45 This underscores the independent
influence of PA and SB on sarcopenia and its parameters.44 Overall, being physically
active across the life course has shown strong associations with better musculoskeletal
health (Figure 2).7

Figure 2: Muscle mass changes across the life course among a very active and a
sedentary old man. Figure adopted from Valenzuela et al.7.

Prior analyses have indicated that few older adults produce PA bouts longer than
10 minutes.46,47 In this context, PA patterns change considerably with aging by displaying
more fragmented daily patterns with shorter active bouts and longer sitting periods
(Figure 3).48–50 These activity patterns can look very different and depend on the
functional status of each individual.48 For instance, while a healthy older adult may
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accumulate activity minutes in one single bout, individuals with functional limitations
might not be able to sustain activity bouts for a long period of time which results in a
more frequent compensatory interchange between PA and SB during a day.48 Research
has shown that fragmented daily patterns are associated with worse physical performance
measures,48 higher fatigability,50 cognitive impairment,51 and a greater mortality rate
among older adults.49 As a consequence, transition states between sedentary and active
behavior may become more important with advancing age.48–51

Figure 3: Physical activity pattern change with aging. Figure provided by Jennifer A.
Schrack, PhD.
1.5 Statement of the Problem
The progressively increasing demographic growth of older adults globally leads to
major challenges for public health and medicine to prevent and combat age-related
diseases such as sarcopenia.7 Due to the absence of effective drugs, PA seems to be the
most promising factor to manage sarcopenia.7 Incorporating various aerobic and
strengthening exercises have shown to provide beneficial effects on the functional ability
in the oldest-old adult population.7 Especially PA, with a focus on resistance exercises, is
recommended in the prevention and management of sarcopenia according to the
10

International Clinical Practice Guidelines for Sarcopenia.13 While progressive resistance
training may enhance muscle strength and physical performance, muscle mass seems to
be less affected by this intervention.52 The improvements in muscle strength and physical
performance may refine activities of daily living such as walking endurance, gait speed,
and stair climbing.53 However, fewer than 10% of older adults achieve the recommended
amount of two strength trainings per week.54,55 Besides reported issues at the training
facilities such as unavailability of type-, age-, and time-specific classes or poor staff
support, worse health conditions caused by injury and illness are stated as the most
common reasons among older adults to avoid participating in resistance training.56
Researchers and clinicians may also consider interventions which are more easily
adopted by older adults.53 The principle that any activity is better than no activity might
also apply for the prevention of sarcopenia. Consequently, feasible and pragmatic daily
PA tasks for vulnerable older adults should receive more attention in the field of
geriatrics. Gaining a better understanding of daily PA behavior and its association with
sarcopenia is of utmost importance to create novel and efficient interventions.
Detailed PA patterns consisting of bouts with various frequencies, intensities, and
durations can be captured by contemporary research-based accelerometers.49,57 Within
this framework, the total volume of PA is specified as an amalgamated metric which
summarizes all performed PA bouts.58 The 2nd edition of the Physical Activity
Guidelines for Americans (PAG) released by the U.S. Department of Health and Human
Services in 2018 suggests that people aged 65 and above should engage in a minimum of
150 minutes of moderate to vigorous intensity physical activity (MVPA).59
Recommended PA bouts of at least 10 minutes which were stated in previous versions of
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PA recommendations, including the PAG 2008 and the global recommendation on PA for
health 2010,60,61 were removed from the recently revised PAG 2018.59 This paradigm
shift occurred based on the growing evidence that PA of any bout duration is associated
with better health outcomes.62 However, the efficacy of the accumulated time spent in
short PA bouts (<10 minutes) as well as long PA bouts (≥10 minutes) compared to the
overall volume of PA is still unknown,63 especially in association with detrimental health
outcomes such as sarcopenia.64,65
To the best of our knowledge, only one study has yet investigated associations of
objectively measured PA patterns compared to the overall volume of PA on defined
sarcopenia and its indicators.66 Nevertheless, not a single study has included short PA
bouts (<10 minutes) to this examination. The assessment of the differentiation between
PA patterns and the total sum of PA in various intensities is highly relevant for the
development of future health guidelines to prevent sarcopenia in the oldest-old adult
population.

1.6 Study Approach
The overall goal of this study is to investigate the associations of accelerometermeasured PA patterns and the total volume of PA with EWGSOP2 defined sarcopenia
and its components, including muscle strength, muscle mass, and physical performance,
among oldest-old adults. We will also complete dose-response associations of different
patterns, volumes, and intensities of PA with sarcopenic conditions and their specified
sarcopenia-related markers. These analyses will be realized with cross-sectional cohort
data provided by the Health, Aging, and Body Composition (Health ABC) study which
offers a comprehensive data collection with measurements on muscle strength, muscle
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mass, physical performance, and accelerometry.67 A sample of 145 oldest-old adults with
a mean age of 88.2 (2.5) years from the metropolitan areas of Memphis, TN and
Pittsburgh, PA helps address our research aims. We hypothesize that PA patterns
comprised of high levels of short MVPA bouts (<10 minutes) are equally important as
the total volume of MVPA with EWGSOP2 defined sarcopenia and its parameters among
oldest-old adults.
This study will contribute valuable knowledge to the current literature.
Addressing this research question will provide information on PA duration and intensity
that can be applied in PA interventions to delay or even prevent the loss in muscle
strength, muscle mass, and physical performance abilities and thus the onset of
sarcopenic conditions among the oldest-old adult population. In the long term,
understanding optimal patterns of PA for pragmatic targets for future interventions and
public health guidelines focusing on sarcopenia and its components can improve the
quality of life and longevity in oldest-old adults.

1.7 Aims and Hypotheses
Aim 1: Examine associations of accelerometer-determined physical behavior
volume and pattern metrics with EWGSOP2 defined sarcopenia and its
components, including muscle strength, muscle mass, and physical performance,
among oldest-old adults. We hypothesize that higher volumes of MVPA, regardless of
its accumulation in short MVPA bouts (<10 minutes) or in long MVPA bouts (≥10
minutes), will demonstrate associations with lower odds of EWGSOP2 defined
sarcopenia and better sarcopenic parameters among oldest-old adults.
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Aim 2: Examine dose-response associations of various accelerometerdetermined physical behavior volume and pattern metrics with EWGSOP2 defined
sarcopenia and its components, including muscle strength, muscle mass, and
physical performance, among oldest-old adults. Physical behavior metrics will be
grouped into tertiles. This enables us to determine health-beneficial doses for different
patterns, volumes, and intensities of physical behavior on EWGSOP2 defined sarcopenia
and its determinants among oldest-old adults. We hypothesize that oldest-old adults with
the highest volumes of MVPA, whether accumulated in short MVPA bouts (<10 minutes)
or in long MVPA bouts (≥10 minutes), will indicate favorable dose-response associations
with EWGSOP2 defined sarcopenia and its individual parameters.
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CHAPTER 2
LITERATURE REVIEW
Since the coining of the term sarcopenia by Rosenberg in 19888 and the official
recognition as a muscle disease in 2016 by the World Health Organization,12 a gradual
increase of scientific interest and awareness about this public health issue has occurred.
The purpose of this literature review is to summarize and discuss crucial findings
regarding the association of various physical behavior metrics with defined sarcopenia
and its related parameters, including muscle strength, muscle mass, and physical
performance, in older adults.

2.1 Methodological Approach for the Literature Review
This literature search was completed by using the Covidence software which is a
literature review manager software and a useful tool to screen research articles and
summarize information from the existing literature. The literature review was conducted
by implementing the following steps: (1) topic-specific literature search in an electronic
database, (2) importing selected literature to Covidence, and (3) including or excluding
relevant literature based on abstract- as well as full-text screening within the software.
Research articles were collected from PubMed using the following Boolean string:
“sarcopenia AND (physical activity OR sedentary behavior) AND (questionnaire OR
self-report OR acceleromet* OR objectively-measur*)”. This procedure identified 391
articles. After additionally screening the reference lists of individual research articles, 9
supplemental studies were included in Covidence. As a result, 400 scientific papers were
evaluated in the initial screening.
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Research articles were included based on the following criteria: 1) observational
studies; 2) community-dwelling population; 3) age 60 and above; 4) measurement of
physical activity by using self-report and/or accelerometer; 5) measurement of muscle
strength; 6) data for associations of PA with sarcopenic determinants including muscle
strength, muscle mass, or physical performance and/or defined sarcopenia. Excluded
were research articles with the following attributes: 1) review articles and meta-analyses;
2) randomized controlled trials; 3) measurements of muscle mass and/or physical
performance alone; 4) accelerometer-assessed data without any information on at least
one of the following physical behavior metrics: total volume of PA, light intensity
physical activity (LIPA), moderate to vigorous physical activity (MVPA), bouts of PA,
total time spent in SB or bouts and breaks in sedentary time. Due to the limited data
among the oldest-old adult population, we decided to collect studies with all older adults
defined at 60+ years of age. In this abstract screening process, a total of 265 studies were
considered as irrelevant and thus excluded from this literature review. The remaining 135
studies were assessed for eligibility by reviewing the full text of the study. This full text
review led to an additional exclusion of 111 studies since they provided outcomes, study
designs, populations or settings which did not match the determined inclusion criteria.
Overall, 24 research articles met the inclusion criteria and were selected for a
comprehensive literature review (Figure 1).
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Figure 4: Literature review summary table from Covidence regarding the associations of
physical behavior metrics with defined sarcopenia and/or its components.
2.2 Association of Physical Activity with Defined Sarcopenia and its Components
among Older Adults
2.2.1 Self-report Measurement of Physical Activity
Overview: 16 out of 24 studies used self-report questionnaires for the assessment
of PA. This high proportion of employing subjective methods was expected since
measuring PA by questionnaire is known to be more cost-effective and simpler to
administer in comparison to accelerometry.68 High costs and a lack of technical expertise
are stated as the most common barriers for applying accelerometers in epidemiological
research.69 Self-report measurements are still considered as a solid method for studies
with large populations.69 In addition, questionnaires provide the ability to evaluate
different types of PA and can be applied for a long period of time.70
Since PA is a multidimensional construct, each instrument has its strengths and
limitations which explains the absence of a gold-standard subjective method.71 The
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International Physical Activity Questionnaire (IPAQ) is still the most used self-report PA
questionnaire globally.72 This also remains true for our literature review in which one
quarter of the studies conducted the IPAQ.
Study Outcomes Review: As illustrated in Table 2, the association of self-report
PA with defined sarcopenia and its components, including muscle strength, muscle mass,
and physical performance, provided conflicting information. These inconsistent results
may be caused by the diversity of applied self-report methods to evaluate PA and the
various approaches to define sarcopenia. Notably, the measurement of gait speed as an
indicator of physical performance was most frequently related with self-report PA.
Several unique findings from the self-report PA studies were of interest.
Structured daily schedules with frequent engagement in active hobbies across the life
course may help to maintain better muscle health among the old-age population.73 The
transition from work life to retirement might be a vital point in time due to critical
alterations on the structure of daily routines.73 Outcomes from a Japanese populationbased cohort study indicated a significant relationship between exercise habits in middle
age and sarcopenia in older age even after adjusting for age, sex, and body mass index.74
Older adults with higher PA levels were more likely to remain in the normal muscle
health state which was described as having muscle strength, muscle mass, and physical
performance above the specified cut-off values for sarcopenia.75 However, according to
longitudinal outcomes from Yu et al.76, once participants were diagnosed with
sarcopenia, the number of returns to a non-sarcopenic condition was low. Based on this
information, higher levels of PA may prevent older adults of becoming sarcopenic but
may not be effective enough to help achieve a return to a non-sarcopenic state.
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Table 2: Characteristics of observational studies looking at associations of self-report physical activity with defined sarcopenia
and/or sarcopenia-relevant metrics
Study Characteristics
Study

Akune et
al. (2014)74

Study
Design

Crosssectional

Alexandre
et al.
(2014)77

Crosssectional

Bann et al.
(2015)78

Crosssectional

Dutra et al.
(2015)79

Crosssectional

Age

65+

60+

70-89

60+

Sample
Size

1000

1149

1130

173

Exposure Information
Country

Japan

Brazil

USA

Brazil

Measurement
Tool

Intervieweradministered
questionnaire

Brazilian version of the
IPAQ

CHAMPS

IPAQ, long form
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Outcome Information
Sarcopenia
Definition

EWGSOP

MS
Measure

Grip
strength

MM
Measure

BIA

EWGSOP

Grip
strength

N/A

Grip
strength

N/A

EWGSOP

Grip
strength

Lee
equation

DXA

Findings
PP
Measure

Main Findings

Gait speed;
RCS; Oneleg standing
time

While current walking
habits indicated no
association with
sarcopenia, individuals
with exercise habits in
middle age had
significantly lower odds
for sarcopenia.

Gait speed

Other than men, women
with low levels of PA
were associated with a
lower likelihood for
sarcopenia.

N/A

Lower-light, higher-light,
and total PA
demonstrated no
association with MS.

Gait speed

Participants (≥ 80 years)
with insufficient PA
levels had higher odds for
a sarcopenic condition.

Gianoudis
et al.
(2015)45

Crosssectional

Hai et al.
(2017)80

Crosssectional

Hai et al.
(2017)81

Crosssectional

Kim et al.
(2019)82

Crosssectional

Mijnarends
et al.
(2016)83

Crosssectional
and
Cohort

Murphy et
al. (2014)75

Crosssectional
and
Cohort

60-86

60-92

60-92

65+

66-93

70-79

162

836

834

3634

2309

2928

Australia

China

China

South
Korea

CHAMPS

IPAQ, long form

IPAQ, long form

N/A

Iceland

N/A

USA

Standardized
questionnaire designed
specifically for the
Health ABC study
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EWGSOP

Knee
extensor
strength

AWGS

Grip
strength

AWGS

Grip
strength

N/A

Grip
strength

EWGSOP

Grip
strength

N/A

Grip
strength

DXA

BIA

BIA

N/A

CT

DXA

RCS; Four
square step
test; TUG

Higher levels of MVPA
suggested no associations
with MS, MM, and PP.

Gait speed

The association between
PA levels and sarcopenia
was not significant in the
multivariate analysis.

Gait speed

The multivariate model
demonstrated no link
between PA and
sarcopenia.

N/A

Higher participation rates
in aerobic and
strengthening exercise
were significantly
associated with better MS
in men and women.

Gait speed

More than 1 hour per
week of MVPA was
correlated with lower
odds of sarcopenia.

Gait speed

Higher levels of PA
lowered the likelihood of
transitioning toward a
sarcopenic state.

Sjöblom et
al. (2020)84

Crosssectional
and
Cohort

66-71

610

Finland

Self-administered
questionnaire

N/A

Grip
strength

DXA

RCS; ability
to squat; gait
speed;
tandem
walk;
standing
with closed
eyes;
modified
SPPB; one
leg stance
performance

Volpato et
al. (2014)85

Crosssectional

65+

538

Italy

Self-administered
questionnaire

EWGSOP

Grip
strength

BIA

Gait speed

Low levels of PA were
not related with
sarcopenia.

China

Validated
questionnaires used in
the China Kadoorie
Biobank study

Gait speed;
RCS; TUG

Higher levels of PA were
significantly correlated
with better grip strength
and better gait speed
measures.

Gait speed

Lower MS, MM, and PP
measures were related
with the joint association
of physical inactivity and
poor insulin sensitivity.

Xu et al.
(2018)86

Yang et al.
(2017)87

Crosssectional

Crosssectional

60+

65+

2633

844

Taiwan

N/A

AWGS

N/A
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Grip
strength

Grip
strength

BIA

DXA

Several PP measures were
positively linked with
continuous PA at 1-hour
intervals. Higher
continuous PA at 1-hour
interval with a total
volume of PA ≥ 2.5 hours
per week was correlated
with better walking speed
and ability to squat.

Yu et al.
(2014)76

Cohort

Zeng et al.
(2016)73

Crosssectional

65+

60+

4000

461

China

China

PASE

N/A

EWGSOP

Grip
strength

AWGS

Grip
strength

DXA

Gait speed

The risk of sarcopenia
was lower in participants
with higher total volumes
of PA. Higher levels of
PA were not correlated
with the reversibility of a
lower risk for sarcopenia.

BIA

Gait speed;
RCS

Only gait speed as a
metric of PP was
positively associated with
physical exercise.

Abbreviations: AWGS: Asian Working Group of Sarcopenia; BIA: bioelectrical impedance analysis; CHAMPS: Community Healthy Activities Model Program for Seniors;
CT: computerized tomography; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; IPAQ: International
Physical Activity Questionnaire; MM: muscle mass; MS: muscle strength; MVPA: moderate to vigorous physical activity; N/A: Not available; PA: physical activity; PASE:
Physical Activity Scale for the Elderly; PP: physical performance; RCS: repeated chair stand test; SPPB: short physical performance battery; TUG: timed up and go test.
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2.2.2 Objective Measurement of Physical Activity
Overview: A total of 9 investigations applied objective measurements to examine
associations of behavioral activity with defined sarcopenia and its parameters.
Accelerometers used in PA research are small wearable devices with the main purpose of
recording accelerations triggered by body movements. This allows the collection of
various PA-related measures in a free-living environment.70 Accelerometry has gained
popularity among researchers in recent decades since its usage solved several limitations
of subjective assessments such as lack of robustness to estimate light or moderate intense
activities or to quantify energy expenditure.71 The issue of recall bias can be reduced with
accelerometers which alleviates the risk of human error.88 The unique capability of
accelerometry to translate objectively measured acceleration counts via designed
algorithms into PA intensity, volume, and duration, or metrics such as energy expenditure
is another advantage over self-report methods.71,88
The ActiGraph (Pensacola, FL, USA) has been the most used accelerometer by
researchers with a utilization rate of more than 50% among published studies according
to a systematic review.89 Based on our literature search, more than half of the collected
studies (5 out of 9 articles) employed ActiGraphs to assess different activity behavior
variables in older adults.
Provided data and information from these scientific articles are summarized in
detail below with a focus on observational findings of the association of various physical
behavior metrics, including the total volume of PA, LIPA, MVPA, and bouts of PA, with
defined sarcopenia as well as sarcopenia-relevant indicators including muscle strength,
muscle mass, and physical performance.
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2.2.2.1 Total Volume of Physical Activity
Overview: The total volume of PA is a summarizing metric which includes the
dimensions of frequency, intensity, and duration of activity bouts.58 Accelerometry has
the ability to provide total activity counts which indicates an estimation of the total time
spent in PA.58
Study Outcomes Review: 4 out of 9 studies from our literature review
investigated the association of the accelerometer-assessed total volume of PA with
defined sarcopenia and its determinants (Table 3). Higher total activity counts were
significantly related with lower odds of sarcopenia.64,90 In this context, Sanchez-Sanchez
et al.64 demonstrated a positive correlation between total activity counts and all
sarcopenia-relevant indicators including muscle strength, muscle mass, and physical
performance. Westbury et al.90 also reported associations of higher accelerometerassessed volumes of PA with a lower likelihood of sarcopenia and better gait speed as a
measure of physical performance. However, converse to the previous findings from
Sanchez-Sanchez et al.64, there were no significant correlations with muscle strength and
muscle mass. In addition, Bann et al.78 reported a link between objectively measured PA
and grip strength in men, but not in women. This gender-specific difference may be
explained by the types of upper limb strengthening activities in which men may partake
more frequently than women.78 While overall levels of PA were inconsistently related
with muscle strength and muscle mass measures, physical performance indicated a
significant association with the total quantity of activity across all collected studies.
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Table 3: Characteristics of observational studies looking at associations of total activity counts with defined sarcopenia and/or
sarcopenia-relevant metrics
Study Characteristics
Study

Bann et al.
(2015)78

Rojer et al.
(2018)91

SánchezSánchez et
al. (2019)64

Westbury
et al.
(2018)90

Study
Design

Crosssectional

Crosssectional

Crosssectional

Crosssectional

Age

70-89

74.4
(72.4 78.0)

78.08
(5.71)

74-84

Sample
Size

1130

80

512

131

Exposure Information
Country

Measurement
Tool

USA

ActiGraph GT3X:
Total PA (min/day)

Netherlands

DynaPort
MoveMonitor:
Active duration
(min/day); Mean
duration of active
period (second/period)

Spain

ActiGraph:
TAC per day

UK

GENEactiv:
Daily time spent in
non-sedentary PA
levels (≥40 acceleration
in milli-g)

Outcome Information
Sarcopenia
Definition

N/A

N/A

FNIH

EWGSOP

MS
Measure

Grip
strength

Grip
strength

Grip
strength

Grip
strength

MM
Measure

N/A

BIA

DXA

DXA

Findings
PP
Measure

Main Findings

N/A

Higher levels of PA
were significantly
associated with better
grip strength in men
but not in women.

Gait
speed

Gait speed as a
measure of PP was
positively correlated
with the overall
volume of PA.

Gait
speed

Defined sarcopenia
and its components,
including MS, MM,
and PP measures,
were positively related
with TAC.

Gait
speed

Higher levels of PA
were linked with
better PP and a lower
likelihood for a
sarcopenic condition.

Abbreviations: BIA: bioelectrical impedance analysis; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older
People; FNIH: Foundation for the National Institutes of Health; MM: muscle mass; MS: muscle strength; N/A: Not available; PA: physical activity; PP: physical
performance; TAC: total activity counts.
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2.2.2.2 Light Intensity Physical Activity
Overview: Metabolic equivalents (METs) can estimate the energy expenditure of
individuals during PA and is often used as an indicator of activity intensity.92 In this
regard, 1 MET signifies the energy expenditure when sitting or lying at rest and increases
during activities in higher intensities.92 The operational definitions of METs for each
activity level are described in Figure 5.93 Light intensity physical activity (LIPA) is
defined by METs of 1.5-2.9 which includes activities such as walking slowly or washing
dishes.94 Health effects of LIPA are poorly understood since most published
epidemiological studies use self-report methods which are less successful in capturing
lower intensity activities.94 A meta-analysis from Ku et al.95 indicated that increased
levels of LIPA provide additional health benefits above and beyond levels of MVPA.
Due to commonly detected limited physical conditions in older adults, LIPA may offer an
effective and feasible opportunity to replace SB which may avoid the onset of related
chronic conditions. Since LIPA appears to be less fatiguing, activities in lower intensity
categories can be integrated into the entire day with higher frequency and comfort for
older adults.
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Figure 5: Operational definitions of metabolic equivalents for each activity category.
Figure adopted from Holtermann & Stamatakis.93

Study Outcomes Review: In total, 4 investigative papers from our literature
search collected LIPA data to analyze its relationship with defined sarcopenia and
sarcopenia-relevant metrics (Table 4). The overall tendency of the study outcomes
indicated that higher volumes of LIPA were not associated with lower odds of sarcopenia
among older adults. While the provided data of the association between LIPA levels and
all sarcopenic determinants were inconsistent, physical performance measures seem to be
the most influenced parameter. In this regard, Scott et al.66 reported that an additional
hour per week in LIPA led to a 12% higher likelihood of better timed up and go test
performance in older adults.
The effect of reducing SB while increasing LIPA tended to diminish the risk of
becoming sarcopenic but lacked statistical significance.64 Significantly lower odds for
sarcopenia appeared after reducing the time spent in LIPA while increasing the time
spent in MVPA among older adults.64 Furthermore, a subdivision of LIPA into two
intensity categories defined as lower-LIPA and higher-LIPA may provide supplemental
information. For instance, Bann et al.78 characterized low-LIPA as minute-by-minute
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acceleration counts between 100 and 1040 while higher-LIPA was identified after
reaching between 1041 and 1951 acceleration counts per minute. In this context, an
additional hour of higher-LIPA led to a 6 kg or a 19% higher performance in grip
strength among men.78 In summary, these study results may conclude just minor effects
of LIPA on muscle strength and muscle mass but a positive association with physical
performance. As a consequence, spending more time in LIPA might not influence muscle
strength and muscle mass but may be important for maintaining physical performance.
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Table 4: Characteristics of observational studies looking at associations of light intensity physical activity with defined
sarcopenia and/or sarcopenia-relevant metrics
Study Characteristics

Exposure Information

Outcome Information

Findings

Study

Study
Design

Age

Sample
Size

Country

Measurement
Tool

Sarcopenia
Definition

MS
Measure

MM
Measure

PP
Measure

Main Findings

Aggio et
al.
(2016)96

Crosssectional

70-92

1268

UK

ActiGraph GT3X:
Time in LIPA
(min/day)

EWGSOP

Grip
strength

MAMC

Gait speed

Gait speed alone was
positively related with the
overall time spent in LIPA.

N/A

Grip
strength

N/A

N/A

Higher-LIPA was positively
associated with MS in men but
not in women.

Bann et
al.
(2015)78

Crosssectional

70-89

1130

USA

ActiGraph GT3X:
Lower-light intensity
PA (min/day); Higherlight intensity PA
(min/day)

SánchezSánchez
et al.
(2019)64

Crosssectional

78.08
(5.71)

512

Spain

ActiGraph:
LIPA (h/day)

FNIH

Grip
strength

DXA

Gait speed

Only minor effects of LIPA on
sarcopenia and its determinants
were indicated.

Scott et al.
(2020)66

Crosssectional

70+

3334

Sweden

ActiGraph GT3X+:
Total LIPA time (h)

EWGSOP2

Grip
strength

iDXA

TUG

Higher volumes of LIPA were
positively associated with MM
and PP.

Abbreviations: DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; EWGSOP2: European Working Group
on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; LIPA: light intensity physical activity; MAMC: mid-upper arm muscle
circumference; MM: muscle mass; MS: muscle strength; N/A: Not available; PA: physical activity; PP: physical performance; SB: sedentary behavior; TUG: timed up
and go test.
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2.2.2.3 Moderate to Vigorous Intensity Physical Activity
Overview: Moderate to vigorous intensity physical activity (MVPA) is the
merged term for the combination of moderate intensity PA which is equivalent to 3-5.9
METs and vigorous-intensity PA which corresponds to the equal or greater amount of 6
METs.97 The 2018 Physical Activity Guidelines for Americans (PAG) suggests that
people aged 65 and above should engage in a minimum of 150 minutes MVPA in order
to improve overall health conditions.59 A strong consensus among epidemiological
experts can be found regarding the positive health benefits of MVPA on reducing allcause mortality.98 Nevertheless, there are still many unanswered questions regarding the
association of MVPA on underlying health conditions including sarcopenia.
Study Outcomes Review: Based on our literature review, 6 articles examined the
association of total MVPA volumes with defined sarcopenia and its parameters (Table 5).
The majority of the collected studies implied significant relationship between high levels
of MVPA and lower odds for a sarcopenic condition. Likewise, better physical
performance measures were significantly correlated with high volumes of MVPA across
all collected studies. While muscle strength also displayed a strong link with MVPA,
muscle mass was inconsistently related with this metric. These findings suggest that
MVPA in older adults may have a more potent impact on the maintenance of muscle
strength and physical performance compared to muscle mass.
Participants with sarcopenia spent significantly less time in MVPA compared to
their counterparts without sarcopenia.66 Furthermore, the odds for a severe sarcopenia
diagnosis were considerably lower among participants with higher daily volumes of
MVPA even after adjusting for several confounding factors.96 Within this framework,
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substituting 1 hour of SB with 1 hour of MVPA per day was significantly related to better
sarcopenia-relevant outcomes.64 Scott et al.66 estimated lower likelihoods of 20%, 12%,
and 66% for diminished muscle strength, muscle mass and physical performance
following an increment of 1 hour per week in MVPA, respectively. In conclusion, MVPA
might play a role in the prevention of sarcopenia.
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Table 5: Characteristics of observational studies looking at associations of moderate to vigorous intensity physical activity with
defined sarcopenia and/or sarcopenia-relevant metrics
Study Characteristics
Study

Study
Design

Aggio et
al.
(2016)96

Crosssectional

Poyatos et
al.
(2016)99

Crosssectional

Cooper et
al.
(2015)100

SánchezSánchez
et al.
(2019)64

Crosssectional

Crosssectional

Age

70-92

65-79

60-64

78.08
(5.71)

Sample
Size

1268

36

1727

512

Exposure Information
Country

Measurement
Tool

Sarcopenia
Definition

UK

ActiGraph GT3X:
Time in MVPA
(min/day)

Spain

ActiGraph GT3X:
PA (min/day) divided
into moderate and
vigorous PA groups

UK

Spain

Outcome Information

Actiheart:
Time spent in MVPA
(min/day)

ActiGraph:
MVPA (h/day)

EWGSOP

Grip
strength

N/A

Grip
strength

N/A

FNIH
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MS
Measure

Grip
strength

Grip
strength

MM
Measure

Findings
PP
Measure

Main Findings

Gait
speed

MS and PP measures
indicated a positive
association with MVPA.
Higher volumes of MVPA
were also related with lower
odds of severe sarcopenia.

N/A

N/A

A positive relationship
between grip strength and
MVPA in older women was
reported.

N/A

RCS;
Standing
balance
time;
TUG
speed

Significant associations of
higher MVPA levels with
better MS and several PP
measures were pointed out.

Gait
speed

Expanding the time spent in
MVPA by 1 hour per day
was significantly associated
with a lower likelihood for
sarcopenia and better MS,
MM, and PP.

MAMC

DXA

Scott et al.
(2020)66

Crosssectional

Westbury
et al.
(2018)90

Crosssectional

70+

74-84

3334

131

Sweden

ActiGraph GT3X+:
Total MVPA time (h)

UK

GENEactiv:
Daily time spent in
MVPA (≥ 100 mg)

EWGSOP2

Grip
strength

EWGSOP

Grip
strength

iDXA

TUG

Higher volumes of MVPA
were significantly associated
with probable or confirmed
sarcopenia. All sarcopeniarelevant parameters were
positively correlated with
MVPA.

DXA

Gait
speed

More time spent in MVPA
demonstrated no association
with sarcopenia and its
components.

Abbreviations: BIA: bioelectrical impedance analysis; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People;
EWGSOP2: European Working Group on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; MAMC: mid-upper arm muscle
circumference; MM: muscle mass; MS: muscle strength; MVPA: moderate to vigorous physical activity; N/A: Not available; PA: physical activity; PP: physical
performance; RCS: repeated chair stand test; TUG: timed up and go test.
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2.2.2.4 Bouts of Physical Activity
Overview: Since the publication of the Physical Activity and Health
recommendation by the Centers for Disease Control and Prevention and the American
College of Sports Medicine in 1995,101 MVPA bouts have been endorsed by PA
epidemiologists over a period of more than 20 years.102 At this point in time, intermittent
bouts of 8 to 10 minutes MVPA were considered as health beneficial as long as the total
volume of 30 minutes MVPA on preferably each day of the week was achieved.101 The
intention of including a PA bout suggestion was to encourage people to be more active by
providing more flexibility regarding the accumulation of the recommended total volume
of MVPA.101
In 2008, the recommendations created by the Physical Activity Guideline for
Americans (PAG) concluded that MVPA bouts should be realized for at least 10 minutes
in order to attain substantial health benefits.60 The recommended guidance of performing
MVPA bouts with a length of 10 minutes or longer was predominantly based on selfreport studies.102 The recently revised 2018 PAG excluded the recommended PA bouts of
at least 10 minutes with the argument that free-living PA was mainly performed
sporadically with a duration lower than 10 minutes.62 Findings from a systematic review
of cross-sectional and prospective cohort studies conducted by Jakicic et al.62 indicated
that any PA bout lower than 10 minutes was still related to better results in a variety of
health-specific outcomes as long as the total recommended volume of PA was
accumulated.
However, there is still a need to investigate and understand PA patterns of
different target groups and their association with various health outcomes. These studies
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may be particularly important for populations who have issues performing PA bouts
longer than 10 minutes. According to research results from Saint-Maurice et al.47, more
than 30% of US adults older than 40 years of age produced zero PA bouts longer than 10
minutes. This proportion is expected to increase even further in the growing old-age
population since the duration of PA bouts tend to decrease progressively with aging.49
In general, knowledge about the efficacy of PA bouts in comparison with the total
volume of PA in older adults is still scarce.63 Additionally, a better understanding of the
relationship between the influence of various MVPA bout durations and health outcomes
would enable better tailored and more effective PA recommendations for older adults.103
Jefferis et al.63 reported a significant association between accumulated sporadic MVPA
bouts with periods of less than 10 minutes among older adults and a decreased risk of allcause mortality. Another study indicated that older adults who achieved the PA
guidelines showed higher muscle mass and physical function measures compared to
inactive participants regardless of the type of accumulation, whether realized in short or
in long bouts.104
Study Outcomes Review: Only one investigation provided information regarding
the association of PA bouts with sarcopenia and its indicators (Table 6). Scott et al.66
reported that the vast majority of various long MVPA bouts (≥10 minutes) was associated
with lower odds for probable or confirmed sarcopenia and their components. Moreover,
each LIPA bout duration from 10-19 minutes to ≥60 minutes indicated positive
correlations with muscle mass and physical performance, but not with muscle strength.66
Overall, these findings implied that various patterns of accumulated PA did not
demonstrate different effects on sarcopenia and its indicators compared to the total
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volume of PA.66 Nevertheless, to the best of our knowledge, no study has investigated the
association of PA bouts lower than 10 minutes with sarcopenia and its individual
components yet.
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Table 6: Characteristics of observational studies looking at associations of physical activity bouts with defined sarcopenia
and/or sarcopenia-relevant metrics
Study Characteristics
Study

Scott et al.
(2020)66

Study
Design

Crosssectional

Age

70+

Sample
Size

3334

Exposure Information
Country

Sweden

Measurement
Tool

Outcome Information
Sarcopenia
Definition

ActiGraph GT3X+:
Total number of bouts
for LIPA and MVPA

EWGSOP2

MS
Measure

Grip
strength

MM
Measure

iDXA

Findings
PP
Measure

Main Findings

TUG

The pattern in which PA was
accumulated did not
influence significant
associations of the total
volume of PA with
sarcopenia and its
parameters.

Abbreviations: DXA: dual-energy X-ray absorptiometry; EWGSOP2: European Working Group on Sarcopenia in Older People 2; LIPA: light intensity physical
activity; MM: muscle mass; MS: muscle strength; MVPA: moderate to vigorous intensity physical activity; PP: physical performance; TUG: timed up and go test.
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2.3 Association of Sedentary Behavior with Defined Sarcopenia and its Components
among Older Adults
2.3.1 Self-report Measurement of Sedentary Behavior
Overview: Independent from PA, sedentary behavior (SB) reveals a negative
impact on human health.105 SB is defined as a waking activity which requires an energy
expenditure of less than or equal to 1.5 METs.105 The total daily amount of sedentary
time may reach its peak at the older age range.106 According to a systematic review
published by Harvey et al.107, accelerometer data demonstrated that 67% of the global
old-age population remained sedentary for more than 8.5 hours per day. These overall
high amounts of sitting time are associated with an increased risk for all-cause mortality
as well as with chronic illnesses such as cardiovascular disease and type 2 diabetes.108
A total of 9 studies from our literature review were collected regarding the
association of SB with defined sarcopenia and its indicators. Two studies applied selfreport measures and 7 assessed SB with accelerometry. Notably, one study used a
combination of self-report and accelerometer tools to evaluate sitting behavior. Similar to
the PA measurement, the application of self-report methods to investigate the link
between SB and health outcomes commonly leads to considerably underestimated
outcomes which attenuates the internal validity of the study. On the other hand, in
comparison to device-based assessments, self-report measures may be very useful for the
gathering of contextual information such as type of performed SB.109
Study Outcomes Review: In sum, 2 studies applied self-report methods in order
to evaluate the association of SB with defined sarcopenia and its determinants (Table 7).
The cross-sectional analysis performed by Gianoudis et al.45 indicated that an increment
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of the total sitting time by 1 hour led to a 33% higher odds for sarcopenia. Higher levels
of TV viewing, on the other hand, were related to lower leg muscle mass.45 These study
results imply that the impact on sarcopenic measures may vary based on the type of
performed SB. A meta-analysis with data from more than 1 million participants showed
that the effect of TV-viewing time was more strongly associated with all-cause mortality
than the daily sitting time.110 Plausible reasons for this difference might be the lack of
sedentary breaks and common dietary behaviors during TV viewing.110,111 In this context,
TV viewing time might also have a more adverse influence on muscle strength, muscle
mass, and physical performance than other types of SB.
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Table 7: Characteristics of observational studies looking at associations of self-report sedentary behavior with defined
sarcopenia and/or sarcopenia-relevant metrics
Study Characteristics

Exposure Information

Outcome Information

Findings

Study

Study
Design

Age

Sample
Size

Country

Measurement
Tool

Sarcopenia
Definition

MS
Measure

MM
Measure

PP
Measure

Main Findings

Bann et
al.
(2015)78

Crosssectional

70-89

1130

USA

CHAMPS

N/A

Grip
strength

N/A

N/A

Total SB time was not
associated with grip
strength.

RCS; Four
square step
test; TUG

Each 1-hour more of total
sitting time per day was
related with higher odds of
sarcopenia. Higher TV
viewing times were linked
with lower leg lean mass.

Gianoudis
et al.
(2015)45

Crosssectional

60-86

162

Australia

CHAMPS

EWGSOP

Knee
extensor
strength

DXA

Abbreviations: CHAMPS: Community Healthy Activities Model Program for Seniors; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working
Group on Sarcopenia in Older People; MM: muscle mass; MS: muscle strength; N/A: Not available; PP: physical performance; RCS: repeated chair stand test; SB:
sedentary behavior; TUG: timed up and go test.
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2.3.2 Objective Measurement of Sedentary Behavior
Overview: In epidemiological research, the device-based assessment of SB is
considered as the more valid and reliable method in a free-living environment compared
to self-report measurements.112 The ActiGraph GT3X is a primarily energy-expenditure
algorithm driven instrument.112 This wearable device can use a specific threshold of
activity counts which should reflect energy expenditure levels of less than 1.5 METs in
order to define SB.112 The activPAL, on the other hand, focuses on physical position
measurements.112 Both devices induce bias owing to the misclassification of SB.112 For
instance, ActiGraphs are less able to differentiate between postures since they fully focus
on the intensity of movements.113 Thus, activities of LIPA are commonly misclassified as
SB and vice versa because standing positions usually fall below the determined activity
counts threshold.113 In contrast, activPALs which have set their main focus on posture are
incapable of finding differences between SB and active sitting or lying with MET values
of more than 1.5 such as several forms of weightlifting.112
While energy-expenditure driven tools such as the ActiGraph may provide more
valid outcomes of PA, the application of posture-directed devices such as the activPAL
are more accurate in terms of assessing SB.112,114 Despite their limitations, both
accelerometers can provide a relatively good estimation of SB volumes and patterns.113
This enables investigators to get a better picture of behavioral patterns and thus of how
and when sitting time is accumulated each day.108
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2.3.2.1 Total Volume of Sedentary Behavior
Study Outcomes Review: Overall, 7 investigations employed accelerometry to
estimate the association of the total volume of SB with defined sarcopenia and its
components (Table 8). In the majority of the collected studies, the significance of the
associations of defined sarcopenia, muscle strength and muscle mass with the total
volume of SB was lacking. However, physical performance seemed to be affected by the
total time spent in SB since most of the studies displayed a significant relationship. These
study results indicate the potentially positive effect of reducing SB on preserving physical
function among older adults.
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Table 8: Characteristics of observational studies looking at associations of total volume of sedentary behavior with defined
sarcopenia and/or sarcopenia-relevant metrics
Study Characteristics

Exposure Information

Outcome Information

Findings

Study

Study
Design

Age

Sample
Size

Country

Measurement
Tool

Sarcopenia
Definition

MS
Measure

MM
Measure

PP
Measure

Main Findings

Aggio et
al.
(2016)96

Crosssectional

70-92

1268

UK

ActiGraph GT3X:
SB time (min/day)

EWGSOP

Grip
strength

MAMC

Gait speed

Lower gait speed was
associated with more
time spent in SB.

Bann et
al.
(2015)78

Crosssectional

70-89

1130

USA

ActiGraph GT3X:
SB time (min/day)

N/A

Grip
strength

N/A

N/A

Grip strength suggested
no relationship with the
total volume SB.

N/A

RCS;
Standing
balance
time;
TUG
speed

Lower MS and TUG
time were correlated
with higher volumes of
SB.

DXA

Four
square
step test;
RCS;
TUG; Gait
speed

MM was negatively
associated with higher
levels of SB.

Cooper et
al.
(2015)100

Reid et al.
(2018)115

Crosssectional

Crosssectional

60-64

65-84

1727

123

UK

Australia

Actiheart:
Time spent sedentary
(hours/day)

activPAL3:
Total SB (h/day)
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N/A

EWGSOP
and FNIH

Grip
strength

Knee
extensor
strength

Rojer et
al.
(2018)91

Crosssectional

74.4
(72.4 78.0)

SánchezSánchez
et al.
(2019)64

Crosssectional

78.08
(5.71)

Scott et al.
(2020)66

Crosssectional

70+

Netherlands

DynaPort
MoveMonitor:
Inactive duration
(h/day); Mean duration
of inactive periods
(minutes/period)

512

3334

80

N/A

Grip
strength

Spain

ActiGraph:
SB (h/day); LIPA
(h/day)

FNIH

Grip
strength

Sweden

ActiGraph GT3X+:
Total SB (h)

EWGSOP2

Grip
strength

Gait speed

Worse gait speed
measures were
correlated with higher
volumes of SB.

DXA

Gait speed

Each 1-hour increase of
total SB was associated
with higher odds of
sarcopenia.

iDXA

TUG

The total volume of SB
was negatively
associated with PP.

BIA

Abbreviations: BIA: bioelectrical impedance analysis; DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People;
EWGSOP2: European Working Group on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; MAMC: mid-upper arm muscle
circumference; MM: muscle mass; MS: muscle strength; N/A: Not available; PP: physical performance; RCS: repeated chair stand test; SB: sedentary behavior; TUG:
timed up and go test.
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2.3.2.2 Bouts and Breaks in Sedentary Time
Overview: While a bout of SB is characterized as an interval of uninterrupted
sitting time, sedentary breaks are described as the PA time of any intensity between two
sedentary bouts.108 Independent of the total time spent in SB, specific sedentary patterns
such as breaking up sedentary time every 20 minutes have been shown to provide
favorable effects on postprandial glucose and insulin levels in overweight or obese
adults.116 Overall, better metabolic health measures have been reported in participants
who exhibited shorter sedentary bouts with a higher frequency of sitting breaks compared
to those who produced prolonged SB with less breaks.117 Therefore, investigations in the
growing elderly community may be even more important since daily sedentary bouts tend
to increase in length with aging.48
Study Outcomes Review: According to our literature search, 3 studies
investigated the association of sedentary bouts or breaks with defined sarcopenia and its
determinants (Table 9). Overall, sedentary breaks indicated non-significant associations
with defined sarcopenia. The correlation between breaks in sedentary time and
sarcopenia-related parameters was analyzed in 2 investigations. Only physical
performance was positively linked with sedentary breaks based on the cross-sectional
analysis from Aggio et al.96. However, Reid et al.115 concluded a lack of significance
regarding this relationship. In addition, another study examined the correlation of sitting
bouts with sarcopenic indicators. Scott et al.66 pointed out that each sedentary period
which lasted longer than 20 minutes was related with worse outcomes of physical
performance. Muscle strength as well as muscle mass, on the contrary, were not
associated with any reported sedentary bout.
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Table 9: Characteristics of observational studies looking at associations of sedentary bouts and breaks with defined sarcopenia
and/or sarcopenia-relevant metrics
Study Characteristics

Exposure Information

Outcome Information

Findings

Study

Study
Design

Age

Sample
Size

Country

Measurement
Tool

Sarcopenia
Definition

MS
Measure

MM
Measure

PP
Measure

Main Findings

Aggio et
al.
(2016)96

Crosssectional

70-92

1268

UK

ActiGraph GT3X:
Breaks in sedentary
time per hour

EWGSOP

Grip
strength

MAMC

Gait speed

Sedentary breaks were
positively related with PP.

DXA

Four
square
step test;
RCS;
TUG; Gait
speed

Breaks of SB implied no
correlations with all
sarcopenia-relevant parameters
after adjusting for various
confounding factors.

iDXA

TUG

Only TUG time as a measure
of PP was positively related
with sedentary bouts.

Reid et al.
(2018)115

Crosssectional

65-84

123

Australia

activPAL3:
Sit-to-stand
transition/day

Scott et al.
(2020)66

Crosssectional

70+

3334

Sweden

ActiGraph GT3X+:
Total number of bouts
for SB

EWGSOP
and FNIH

Knee
extensor
strength

EWGSOP2

Grip
strength

Abbreviations: DXA: dual-energy X-ray absorptiometry; EWGSOP: European Working Group on Sarcopenia in Older People; EWGSOP2: European Working Group
on Sarcopenia in Older People 2; FNIH: Foundation for the National Institutes of Health; MAMC: mid-upper arm muscle circumference; MM: muscle mass; MS: muscle
strength; PP: physical performance; RCS: repeated chair stand test; SB: sedentary behavior; TUG: timed up and go test.
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2.3.2.3 Activity Fragmentation
Overview: Epidemiological research shows that the activity profile changes
substantially with aging by displaying shorter PA bouts118 and longer bouts of SB.119
Older adults often have difficulty sustaining PA for an extended period of time.48–50 This
may lead to a frequent compensatory interchange of PA and SB during a day.48 Frequent
transition states between a minute-by-minute captured sedentary and active behavior via
accelerometry indicate a higher PA fragmentation which have been previously shown to
be associated with worse health status in older adults.48–51
To the best of our knowledge, only one study has looked at the associations of
activity fragmentation with sarcopenia and its indicators.45 However, physical behavior
metrics were assessed via self-report in this study which may have diminished the
validity of the calculated activity fragmentation.45 An investigative approach of applying
accelerometry to identify the association of activity fragmentation with sarcopenia status
and its parameters is missing. Activity fragmentation can be estimated with the active-tosedentary transition probability (ASTP) index which is calculated by dividing the number
of PA bouts with the sum of minutes spent in PA (Figure 5).48 Utilizing the active-tosedentary transition probability (ASTP) index in epidemiological studies might enable
researchers to obtain a more profound understanding of fragmented activity patterns
among oldest-old adults which may present crucial insights into age-related muscle
changes.
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Figure 6: Calculation of the activity-to-sedentary transition probability. Figure provided
by Jennifer A. Schrack, PhD.
2.4. Strengths and Limitations of Applying Subjective- and Objective Measurement
Methods in Studies with Older Adults
As previously indicated, selecting the appropriate measurement tool to evaluate
PA or SB in a free-living environment is an important component of the research
methodology with pivotal consequences on the validity and reliability of the study
outcomes. Prior to choosing a suitable measure of PA or SB, imperative attributes such as
the evidence-based quality of each methodological approach and the benefit-cost analysis
should be considered.71 Study characteristics, population characteristics, instrument
characteristics, and activity characteristics are factors to contemplate when selecting the
best possible method of activity evaluation.88 The most commonly used approach to
assess PA in epidemiological research is still the self-report questionnaire.120
Questionnaires are described as valuable and cost-effective instruments to measure
various types of PA, whether these activities are performed statically, such as
weightlifting, or dynamically, such as walking.70 In addition, owing to their simple
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operationality for responder and respondent, subjective measures are advantageous in
studies with large sample sizes as well as long time periods.70
However, PA is highly complex and consists of a broad activity spectrum
regarding the volume and intensity.58 This multicomponent shape of PA leads
involuntarily to an incidental recall bias and thus to an over- or underestimation of the
test results which is caused by the inability of self-report questionnaires to obtain precise
minute-by-minute measures.121 Similar to that, SB measures assessed via subjective
methods also commonly experience underestimation of the true study outcomes.122
Accelerometry, on the other hand, can translate body acceleration counts into
measures of energy expenditure.70 The correct utilization of accelerometers enables
investigators to collect more accurate information on the volume and frequency of
various intensities.70 However, activities such as different forms of strength training or
cycling are often not accurately detected by accelerometry.70
Strengths and limitations of PA measurement methodologies also vary between
the differences of population attributes, including age, gender, body weight, or co-morbid
conditions, which lead to even more pronounced difficulties of selecting an effective and
accurate assessment method.71 For instance, activity patterns experience substantial
changes across the life course with overall steady decreases of PA levels from young to
old.118 Due to commonly diminished physical functions or multimorbid conditions, older
adults show large dissimilarities regarding the type and intensity of PA compared to the
younger population.123 In this regard, older adults usually exhibit high levels of LIPA
such as casual walking or different types of household tasks which may be difficult to
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capture via self-report questionnaires owing to their incorrect conceptualization of this
intensity range.124
Additionally, most of the self-report assessments substantially underestimate the
actual levels of SB and frequently record only about a half of the accelerometer
measurements among older adults.125 The application of accelerometry in old-age
population studies helped alleviating parts of the issues by being able to collect low
activity levels and by limiting recall bias.124
However, the variety of accelerometer types and the different data collection and
processing criteria provides challenges for researchers to select the best possible device
for measuring PA and SB. Age-specific data collection protocols such as device
placement or sampling frequency as well as data processing criteria such as filters, epoch
length, non-wear time definition, cut-points, and algorithms are imperative settings which
need to be carefully considered.89 In this regard, the misclassification of behavioral
activities in which most accelerometers exhibit limited functional abilities to differentiate
between SB and LIPA is considered as a huge limitation of objective measurements.112
For instance, while the activPAL as a posture-focused device may ignore active sitting
such as weightlifting, the ActiGraph as an energy expenditure-prone wearable may
disregard passive standing.112,126

2.5 Literature Review Summary
The broad spectrum of activity behavior in terms of length, intensity, and
frequency seems to influence sarcopenia and its components including muscle strength,
muscle mass, and physical performance. Our systematic literature review implied positive
associations of LIPA with physical performance. In this context, LIPA might become
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more important with advancing age since low intensities can be endured for a longer
period of time and are easier to perform with higher frequencies during a day. Higher
volumes of LIPA also lead to a considerable reduction of SB and its potentially
associated negative consequences on muscle health.
MVPA seems to be the most effective type of intensity to reduce the odds of
sarcopenia according to our systematic literature search. Implementing higher levels of
MVPA in daily routines may be essential for lowering the risk of a sarcopenia diagnosis.
However, as previously discussed, MVPA may be difficult to sustain for long time
periods by older adults. Accumulated activity bouts with time periods of less than 10
minutes seem to be understudied despite their common presence throughout day-to-day
activity patterns among the old-age population. To the best of our knowledge, no study
has investigated the association of short sporadic activity bouts (<10 minutes) with
defined sarcopenia and its individual components. Identifying this relationship via
observational studies may fill a valuable gap in geriatric research.
In contrast to the mainly positive effects of PA, SB shows rather adverse
implications on sarcopenia-related physical performance measures. Long sedentary bouts
and short sitting breaks presented an inverse relationship with physical performance
among older adults. Notably, insufficient information was available regarding the
association of activity fragmentation with sarcopenia and its parameters. The activity
fragmentation might indicate a useful marker for deteriorated muscle health among older
adults.
Across the study outcomes of our literature review, higher volumes of PA and
lower volumes of SB were associated with better physical performance regardless of the
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provided bout length and intensity. Engaging in activities with higher intensity might
play a role to obtain an additional positive effect on muscle strength and mass and thus
lower the odds for sarcopenia. Short MVPA bouts (<10 minutes), which might be better
achievable for older adults, may provide enough stimuli to the muscles in order to lower
the odds of sarcopenia and to improve sarcopenia-relevant parameters. In summary,
investigating the relationship between the whole spectrum of activity behavior and
sarcopenia among older adults provides huge opportunities to address this growing
geriatric health issue.
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CHAPTER 3
METHODS

3.1 Introduction
This secondary analysis will evaluate associations of accelerometer-measured PA
patterns and total volume of PA with EWGSOP2 defined sarcopenia and its indicators,
including muscle strength, muscle mass, and physical performance, among oldest-old
adults. Cross-sectional cohort data from the Health, Aging, and Body Composition
(Health ABC) study helps address this research question. The Health ABC study is an
observational investigation with the main purpose of collecting information on a
multitude of risk factors, encompassing weight-related health conditions and behavioral
determinants which may lead to functional decline and loss of independence among
healthy community-dwelling older adults. Their valuable data collection of measurements
on body composition, strength and function as well as accelerometer-assessed PA in a
sample of oldest-old adults contributes to the realization of our defined investigative
aims.67

3.2 Participants
A study cohort composed of 3075 community-dwelling black and white men and
women aged 70-79 years at baseline were randomly recruited from the metropolitan areas
of Memphis, TN and Pittsburgh, PA. Participants were excluded from the study if they
demonstrated: 1.) difficulties to walk one quarter of a mile or to climb 10 steps without
resting; 2.) difficulties with instrumental activities of daily living; 3.) a history of cancer
treatment in the last 3 years; 4.) a plan to move out of the geographic study area in the
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next 3 years. Baseline data of clinical assessments as well as home interviews were
gathered between April 1997 and June 1998. All recruited participants were followed for
a total of 16 years with various subjective and objective evaluations each year. Written
informed consent was given from each involving study subject. Furthermore, the
institutional review boards from the University of Tennessee and the University of
Pittsburgh approved the investigation.
Cross-sectional data from year 16 was used for this analysis due to the availability
of measures of muscle strength, body composition, physical performance, and
accelerometry. The primary sample was analyzed for associations of various behavior
metrics, including total activity counts, total moderate to vigorous physical activity
(MVPA) time, total light intensity physical activity (LIPA) time, total sedentary behavior
(SB) time, total short MVPA bouts (<10 minutes) duration, total long MVPA bouts (≥10
minutes) duration, total number of sedentary breaks, and the active-to-sedentary
transition probability (ASTP), with handgrip strength only, which is stated as the main
indicator of sarcopenia and allows the definition of a probable sarcopenic state according
to the EWGSOP2.18 One-hundred forty-seven participants from the Memphis, TN and
Pittsburgh, PA region were included in the primary sample which was based on the
availability of handgrip strength data tested on both hands and valid accelerometer
measures recorded for at least 4 days.127
As reported by EWGSOP2, confirmed sarcopenia is specified as a combination of
low handgrip strength and low appendicular lean mass. An additional detection of low
gait speed measures concludes a severe sarcopenic condition.18 Consequently, a
subsample of the primary samples was created which required valid data of handgrip
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strength, appendicular lean mass, gait speed, and accelerometry. A total of 87 participants
located in the Memphis area were available for the subsample analysis. The subsample
was used to examine the relationships of various physical behavior metrics with probable,
confirmed, and severe sarcopenia and their individual components including handgrip
strength, appendicular lean mass, and gait speed.

3.3 Study Protocol
3.3.1 Sarcopenia-Related Metrics
3.3.1.1 Muscle Strength
Upper limb muscle strength was measured with the help of an isometric hand-held
dynamometer (Jaymar, JLW Instruments, Chicago, IL) for handgrip strength. The test
was conducted two times for each hand with the mean of all four evaluations used for the
analysis. Participants who reported severe hand pain or recent surgery were excluded
from the study.

3.3.1.2 Muscle Mass
Total fat mass and appendicular lean mass were evaluated using whole body DXA
(Hologic QDR 4500, software version 8.21, Bedford, MA) scans which were solely
performed in Memphis and included as part of the subsample examination. The
appendicular lean mass was quantified by summarizing the lean mass in arms and legs.

3.3.1.3 Physical Performance
Gait speed was applied as a measurement of physical performance among the
sample of oldest-old adults. In this regard, a 20-meter course marked by an orange cone
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at the end of the track was created. Participants were instructed to walk along the course
with their usual pace from a specified starting point to the orange cone. The timer was
started when the participant crossed the starting line and was stopped following the first
step after the finish line. Moreover, the usage of walking aids, such as a cane or walkers,
were allowed during the evaluation process.

3.3.2 Physical Activity Assessment
3.3.2.1 Accelerometry
Participants were instructed to wear an ActiGraph GT3X+ accelerometer
(ActiGraph, Pensacola, Florida, USA) on their right hip for 7 consecutive days. The
monitors were worn during all waking hours except water-related activities such as
swimming and taking a bath or a shower. In addition, participants were instructed to take
off the device prior to sleep time and put it back on after getting up in the morning.
Three-axis acceleration data in free-living conditions were captured by applying 1 second
epoch periods. The analog acceleration signals were digitized by a 12-bit Analog to
Digital Converter with the sampling frequency of 80 Hertz and passed through a digital
filter that band limits the accelerometer to the frequency range of 0.25 to 2.5 Hertz in
order to efficiently detect human motions. Afterwards, movement data from all eligible
participants were uploaded to the ActiLife software (Version 6.5.1; ActiGraph,
Pensacola, FL, USA) to manage and analyze the collected information.

3.3.3 Covariates
Demographic factors, including age, gender, race, and education level, were
identified with an interviewer-administered questionnaire at study baseline. Body mass
56

index (BMI) data was calculated by taking the body weight (kg) and dividing by the
height (meters) squared. A calibrated standard balance beam scale and a Harpenden
stadiometer (Holtain Ltd, Crosswell, UK) were applied to measure the weight and height,
respectively. Smoking status was the only measure determined at year 1 and was included
as a covariate in our study since a previous meta-analysis has shown that cigarette
smoking might contribute to the development of sarcopenia.128 Accelerometer wear time
was quantified as described in Chapter 3.3.2.1. Furthermore, the prevalence of physiciandiagnosed chronic conditions, including diabetes, hypertension, history of cardiovascular
disease, and history of cancer, were also included as potential confounders to the
analysis. These data were ascertained by algorithms based on self-reports and medication
use.

3.4 Data Analysis
3.4.1 Primary Outcome
Sarcopenia was our primary outcome of interest. Sarcopenic indicators included
muscle strength, muscle mass, and physical performance measures.2 Cut points for
sarcopenia-associated parameters were provided by the revised definition of the European
Working Group on Sarcopenia in Older People 2 (EWGSOP2)18. Probable, confirmed, or
severe sarcopenia were defined using low upper limb muscle strength evaluated by a
calibrated handgrip dynamometer (handgrip strength: <27 kg for men and <16 kg for
women), low muscle mass tested by a Dual-energy X-ray absorptiometry (appendicular
lean mass: <20 kg for men and <15 kg for women), and low physical performance
assessed by a 20-m usual walking speed test (gait speed: ≤0.8 m/s).18 We examined each
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sarcopenic condition as a dichotomous variable and each sarcopenia-related metric as a
continuous variable.

3.4.2 Primary Exposures
3.4.2.1 Physical Behavior Volume Metrics
The total volume of various physical behavior metrics including sedentary
behavior (SB), light intensity physical activity (LIPA), and moderate to vigorous
intensity physical activity (MVPA) were determined using the ActiGraph GT3X+
accelerometer data. We identified the total minutes of PA per day (at any bout length) of
total activity counts, LIPA, MVPA, and SB. The classification of the overall time spent in
different physical behavior intensities was determined using counts per minute (cpm)
intensity threshold values. In this context, SB was categorized as <100 cpm,129 LIPA was
categorized as 100-1040 cpm,130 and MVPA was categorized as ≥1041 cpm.130
Participants were excluded from the study when they did not provide ≥4 days of valid
accelerometer data of 10 hours per day.127

3.4.2.2 Physical Behavior Pattern Metrics
We examined MVPA split into bouts lasting <10 minutes and ≥10 minutes. This
enabled us to compare the efficacy of short MVPA bouts (<10 minutes) and long MVPA
bouts (≥10 minutes) with the total volume of MVPA on EWGSOP2 defined sarcopenia
and its components. The selected duration of these 10 minute intensity bouts was based
on the PA recommendations imposed by the PAG 2008 and the World Health
Organization.60,61 Furthermore, although bouts were removed in the most recent 2018
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PAG,59 there is a need for future research to understand how the accumulation of PA
influences health outcomes.62
We investigated the associations of the total number of sedentary breaks and
activity fragmentation with sarcopenic status and its components. A sedentary break was
registered when participants provided ≥100 cpm for at least 1 minute following a
sedentary bout. The activity fragmentation was quantified with the active-to-sedentary
transition probability (ASTP) index. This index gave us an estimation of the
fragmentation level of the provided PA patterns. ASTP was computed for each day and
averaged across valid days to derive a single measure for each participant.48 To calculate
activity fragmentation in Health ABC, we used the number of breaks in SB divided by
the total sum of minutes spent in PA. Higher activity fragmentation represents more
interruptions in activity.

3.5 Statistical Analyses
Participant characteristics comprised of baseline demographic data (age, gender,
race, and education level) and at the year 16 visit accelerometer measures of physical
behavior metrics as well as year 16 visit sarcopenia-related metrics were summarized and
expressed as mean (standard deviation) or median (interquartile range) for continuous
variables or as frequency and percentage for categorical variables. Differences of
participant baseline characteristics by sarcopenic status were determined by independent
samples t-tests or Mann-Whitney U tests for continuous variables and chi-square tests for
categorical variables.
For each analysis described below we used the following variables as primary
exposures: total activity counts, total MVPA time (min/day), total LIPA time (min/day),
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total SB time (min/day), total MVPA minutes in short bouts (<10 minutes in duration;
min/day), total MVPA minutes in long bouts (≥10 minutes in duration; min/day), total
number of sedentary breaks (number of breaks/day), and ASTP (number of sedentary
breaks / total PA time).
Multivariate linear regression models were employed to determine the crosssectional association of each PA variable with sarcopenia-relevant indicators as
continuous variables including handgrip strength, appendicular lean mass, and gait speed.
In order to evaluate the odds for EWGSOP2 defined probable, confirmed, and severe
sarcopenia diagnosis, binomial logistic regression models were used. This provided
clinical relevance since we were able to understand whether sarcopenia as our primary
outcome is associated with distinct PA behaviors and patterns. The odds of probable,
confirmed, and severe sarcopenia were estimated for incrementally higher levels of total
activity counts, total MVPA time (per 5 min/day), total LIPA time (per 60 min/day), total
SB time (per 60 min/day), total MVPA <10 minute bout duration (per 5 min/day), total
MVPA ≥10 minutes bout duration (per 5 min/day), total number of sedentary breaks (per
1 number of sedentary breaks/day), and ASTP (per 0.1 ASTP).
These linear and logistic regression models were adjusted for age, gender, race,
education, and accelerometer wear time in model 1. In model 2, we adjusted for the
covariates presented in model 1 plus lifestyle factors including BMI and smoking status.
Model 3 provided adjustments for all covariates presented in model 2 plus chronic health
conditions including diabetes, hypertension, history of cardiovascular disease, and history
of cancer.
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We also examined the dose-response associations of the total volume of PA and
PA patterns on EWGSOP2 defined probable sarcopenia, confirmed sarcopenia, and
severe sarcopenia among this oldest-old adult population sample. This provided crucial
information on the linearity or non-linearity of the relationships and whether threshold
levels exist for activity behaviors in association with sarcopenia status. Dose-response
associations of behavioral activity metrics, including total activity counts, total MVPA
time (min/day), total LIPA time (min/day), total SB time (min/day), total MVPA <10
minute bout duration (min/day), total MVPA ≥10 minute bout duration (min/day), total
number of sedentary breaks (number of breaks/day), and ASTP (number of sedentary
breaks / total PA time), with EWGSOP2 defined probable sarcopenia, confirmed
sarcopenia, and severe sarcopenia were evaluated. Categorical variables were created for
each PA metric by dividing them into tertiles or groups. Participants were allocated in
three equally sized tertiles based on their level of total activity counts, total LIPA time,
total SB time, total MVPA <10 bout duration, total number of sedentary breaks, and
ASTP. The first (lowest) tertile was considered the reference group. For the total volume
of MVPA, three groups were generated in which 0-5 minutes represented the first group,
5-10 minutes the second group, and ≥10 minute the third group in order to draw a clearer
picture of the statistical results. Due to the expected low presence of the overall minutes
spent in any long MVPA bouts (≥10 minute) among oldest-old adults, participants were
either administered to the group which provided not a single long MVPA bout period or
to the group with at least some amount of long MVPA bout duration.
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A two-tailed hypothesis testing with an alpha level of 0.05 proved statistical
significance of these examinations. All data were analyzed and illustrated using the
statistical software R-studio (R Foundation for Statistical Computing, Vienna, Austria).
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CHAPTER 4
RESULTS

4.1 Primary Sample
4.1.1 Participant Characteristics
The primary sample included 145 participants with valid handgrip strength and at
least 4 days of 10 hours per day of accelerometer wear. One participant was excluded due
to irregularly high acceleration counts, likely caused by accelerometer malfunction. Table
10 presents characteristics of the final 145 participants. Fifty-two (35.9%) individuals
were categorized as probable sarcopenic based on the applied EWGSOP2 criteria. The
mean age was 88.2 (2.5) years and 81 (55.9%) were women, 45 (31.0%) were black race,
and 92 (63.4%) individuals completed a postsecondary degree. Participants spent on
average 9.6 (10.4) minutes per day or 1.1% (1.2%) of the accelerometer wear time in
MVPA, 151.3 (58.7) minutes per day or 18.0% (7.1%) in LIPA, and 686.6 (128.0)
minutes per day or 80.8% (7.8%) in SB. The mean handgrip strength of men was 28.2
(6.3) kg and for women 18.0 (5.1) kg. Significant differences in handgrip strength
between the nonsarcopenic group (men: 32.5 (4.6) kg; women: 20.5 (3.6) kg) and
probable sarcopenic group (men: 22.8 (3.4); women: 12.2 (3.2) kg) were identified. In
addition, significant differences were found among the data of education level, race, total
time spent in MVPA, total time spent in MVPA bouts of <10 minutes, and total time
spent in MVPA bouts of ≥10 minutes. However, no differences between groups regarding
the average minutes of accelerometer wear time, total activity counts, LIPA, SB, number
of sedentary breaks, and ASTP were discovered.

63

Table 10: Participant characteristics of the primary sample

Demographic factors
Age, years, mean (SD)
Women, n (%)
Race, n (%), black
Education, n (%), postsecondary
Site, n (%), Memphis
Lifestyle factors
BMI (kg/m2), mean (SD)
Current smoker, n (%)
Chronic health conditions
Diabetes, n (%)
Hypertension, n (%)
History of cardiovascular disease, n (%)
History of cancer, n (%)
Muscle strength
Handgrip strength (kg), mean (SD)
Handgrip strength men (kg), mean (SD)
Handgrip strength women (kg), mean (SD)
Accelerometer
Average minutes of weartime (min/day), mean (SD)
TAC (counts/day), mean (SD)
% time MVPA, median (IQR)
% time MVPA, mean (SD)
% LIPA, mean (SD)
% SB, mean (SD)

Total sample
(n = 145)

Nonsarcopenic
(n = 93)

Probable sarcopenic
(n = 52)

p-value for difference

88.2 (2.5)
81 (55.9%)
45 (31.0%)
92 (63.4%)
103 (71.0%)

88.2 (2.7)
57 (61.3%)
35 (37.6%)
57 (61.3%)
67 (72.0%)

88.3 (2.3)
24 (46.2%)
10 (19.2%)
35 (67.3%)
36 (69.2%)

0.75
0.11
0.03
<0.01
0.87

27.1 (4.6)
4 (2.8%)

27.52 (4.7)
2 (2.2%)

26.2 (4.5)
2 (3.8%)

0.10
0.95

40 (27.6%)
109 (75.2%)
50 (34.5 %)
42 (29.0%)

26 (28.0%)
70 (75.3%)
33 (35.5%)
29 (31.2%)

14 (26.9%)
39 (75.0%)
17 (32.7%)
13 (25.0%)

1.00
1.00
0.88
0.55

22.5 (7.6)
28.2 (6.3)
18.0 (5.1)

25.1 (7.1)
32.5 (4.6)
20.5 (3.6)

17.9 (6.3)
22.8 (3.4)
12.2 (3.2)

<0.01
<0.01
<0.01

847.6 (119.8)
244,233 (104,544)
0.7 (0.3, 1.6)
1.1 (1.2)
18.0 (7.1)
80.8 (7.8)

837.5 (107.7)
248,011 (107,972)
0.9 (0.4, 1.9)
1.3 (1.3)
18.7 (7.1)
80.0 (7.9)

865.6 (138.0)
237,475 (98,779)
0.5 (0.3, 1.0)
0.8 (1.0)
16.9 (6.8)
82.4 (7.3)

0.21
0.55
<0.01
<0.01
0.14
0.08
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5.7 (3.2, 13.2)
6.5 (3.3, 15.7)
3.9 (2.3, 8.0)
<0.01
MVPA (min/day), median (IQR)
9.6
(10.4)
11.1
(11.0)
6.9
(8.6)
<0.01
MVPA (min/day), mean (SD)
151.3 (58.7)
154.8 (57.3)
145.2 (61.3)
0.36
LIPA (min/day), mean (SD)
686.6 (128.0)
671.6 (121.7)
713.5 (135.6)
0.07
SB (min/day), mean (SD)
5.4 (3.2, 10.9)
6.4 (3.3, 13.8)
3.9 (2.3, 8.0)
<0.01
MVPA in bouts <10 min (min/day), median (IQR)
8.5 (8.8)
9.6 (8.9)
6.6 (8.3)
<0.01
MVPA in bouts <10 min (min/day), mean (SD)
0.0 (0.0, 0.0)
0.0 (0.0, 0.0)
0.0 (0.0, 0.0)
<0.01
MVPA in bouts ≥10 min (min/day), median (IQR)
1.1 (3.2)
1.5 (3.8)
0.3 (1.5)
<0.01
MVPA in bouts ≥10 min (min/day), mean (SD)
Number of sedentary breaks (No. of breaks/day),
69.5 (18.9)
69.5 (15.6)
69.4 (23.8)
0.99
mean (SD)
0.47 (0.11)
0.46 (0.12)
0.49 (0.10)
0.12
ASTP, mean (SD)
Notes: Bold values are significant. All data are mean +/- SD (independent samples t tests), except median (interquartile range) (Mann-Whitney U tests) and
proportions (chi-square test). The active-to-sedentary transition probability index is calculated by dividing the total number of breaks in sedentary behavior
with the sum of minutes spent in physical activity.
Abbreviations: ASTP: active-to-sedentary transition probability; BMI: body mass index; LIPA: light intensity physical activity; MVPA: moderate to vigorous
physical activity; SB: sedentary behavior; TAC: Total activity counts.
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4.1.2 Associations of Physical Behavior Metrics with Probable Sarcopenia (Binomial
Logistic Regressions)
Volumes: Table 11 presents the odds ratios for the associations of physical
behavior volume metrics with probable sarcopenia determined by EWGSOP2. After
adjusting for age, gender, race, education, and accelerometer wear time (model 1), each 5
minute higher per day of MVPA was related with a 28% (95% CI 0.57 to 0.92) lower
likelihood for probable sarcopenia. This association remained significant following
further adjustments for lifestyle factors including BMI and smoking status (OR=0.73,
95% CI 0.58 to 0.92, model 2) as well as chronic health conditions such as diabetes,
hypertension, cardiovascular disease, and cancer (OR=0.73, 95% CI 0.57 to 0.92, model
3). There were no significant associations of total activity counts, LIPA, and SB with
probable sarcopenia.
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Table 11: Odds ratios for the associations of physical behavior volume metrics with
probable sarcopenia
Dichotomous (yes/no)
Probable sarcopenic
OR (95% CI)
Physical behavior volumes
TAC (per 1 SD (104,544 counts))
Model 1
0.79 (0.54 to 1.18)
Model 2
0.78 (0.52 to 1.16)
Model 3
0.77 (0.51 to 1.15)
Total MVPA (per 5 minutes higher)
Model 1
0.72 (0.57 to 0.92)
Model 2
0.73 (0.58 to 0.92)
Model 3
0.73 (0.57 to 0.92)
Total LIPA (per 60 minutes higher)
Model 1
0.81 (0.55 to 1.19)
Model 2
0.83 (0.56 to 1.22)
Model 3
0.82 (0.55 to 1.21)
Total SB (per 60 minutes higher)
Model 1
1.30 (0.91 to 1.84)
Model 2
1.27 (0.89 to 1.81)
Model 3
1.28 (0.89 to 1.84)
Notes: Bold values are significant. Probable sarcopenia is defined using low upper limb muscle
strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg
for women).
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity;
OR (95% CI): odds ratio (95% confidence interval); SB: sedentary behavior; TAC: Total activity
counts.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular
disease, history of cancer)

Patterns: Regarding the associations of physical behavior pattern metrics with
probable sarcopenia in Table 12, we found that 5 minutes per day higher levels of short
MVPA bouts (<10 minutes) were associated with 27% (95% CI 0.56 to 0.96) lower odds
for a probable sarcopenia diagnosis in the final adjusted model. For longer MVPA bouts
(≥10 minutes), each 5 minute more per day demonstrated a 69% (95% CI 0.10 to 0.95)
lower likelihood for probable sarcopenia after final adjustment. Sedentary breaks and
ASTP were not associated with probable sarcopenia.
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Table 12: Odds ratios for the associations of physical behavior pattern metrics with
probable sarcopenia
Dichotomous (yes/no)
Probable sarcopenic
OR (95% CI)
Physical behavior patterns
MVPA <10 minute bouts (per 5 minutes higher)
Model 1
0.73 (0.56 to 0.95)
Model 2
0.74 (0.57 to 0.96)
Model 3
0.73 (0.56 to 0.96)
MVPA ≥10 minute bouts (per 5 minutes higher)
Model 1
0.30 (0.10 to 0.91)
Model 2
0.30 (0.10 to 0.94)
Model 3
0.31 (0.10 to 0.95)
Number of sedentary breaks (No. of breaks/day)
Model 1
1.00 (0.98 to 1.02)
Model 2
1.00 (0.98 to 1.02)
Model 3
1.00 (0.98 to 1.02)
ASTP (per 0.1 ASTP)
Model 1
1.29 (0.94 to 1.79)
Model 2
1.26 (0.91 to 1.74)
Model 3
1.25 (0.90 to 1.73)
Notes: Bold values are significant. Probable sarcopenia is defined using low upper limb muscle
strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg
for women). The active-to-sedentary transition probability index is calculated by dividing the total
number of breaks in sedentary behavior with the sum of minutes spent in physical activity.
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous
physical activity; OR (95% CI): odds ratio (95% confidence interval).
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular
disease, history of cancer)

4.1.3 Associations of Physical Behavior Metrics with Handgrip Strength
(Multivariate Linear Regressions by Gender)
Applying multivariate linear regressions by gender among the primary sample (Table 13
and Table 14) provided no statistically significant association of any physical behavior
volume or pattern variable with handgrip strength.
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Table 13: Linear regression associations of physical behavior volume metrics with
handgrip strength by gender
Handgrip strength (kg)
ß (95% CI)
Men (n = 64)
Women (n = 81)
Physical behavior volumes
TAC (per 1 SD (104,544 counts))
Model 1
0.69 (-0.84 to 2.22)
0.59 (-0.63 to 1.82)
Model 2
0.91 (-0.67 to 2.49)
0.62 (-0.62 to 1.86)
Model 3
0.71 (-0.86 to 2.27)
0.41 (-0.91 to 1.72)
Total MVPA (per 5 minutes higher)
Model 1
0.53 (-0.09 to 1.14)
0.63 (-0.04 to 1.30)
Model 2
0.58 (-0.04 to 1.20)
0.58 (-0.10 to 1.28)
Model 3
0.45 (-0.16 to 1.07)
0.57 (-0.13 to 1.28)
Total LIPA (per 60 minutes higher)
Model 1
0.04 (-1.50 to 1.58)
0.98 (-0.24 to 2.20)
Model 2
0.13 (-1.43 to 1.69)
0.93 (-0.33 to 2.18)
Model 3
0.18 (-1.39 to 1.74)
0.70 (-0.66 to 2.06)
Total SB (per 60 minutes higher)
Model 1
-0.24 (-1.62 to 1.13)
-0.95 (-2.06 to 0.15)
Model 2
-0.34 (-1.73 to 1.06)
-0.90 (-2.04 to 0.24)
Model 3
-0.33 (-1.72 to 1.07)
-0.72 (-1.95 to 0.52)
Notes: Bold values are significant.
Abbreviations: ß (95% CI): Beta coefficient (95% confidence interval); LIPA: light intensity physical
activity; MVPA: moderate to vigorous physical activity; SB: sedentary behavior; TAC: Total activity
counts.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease,
history of cancer)
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Table 14: Linear regression associations of physical behavior pattern metrics with
handgrip strength by gender
Handgrip strength (kg)
ß (95% CI)
Men (n = 64)
Women (n = 81)
Physical behavior patterns
MVPA <10 minute bouts (per 5 minutes higher)
Model 1
0.47 (-0.30 to 1.23)
0.65 (-0.08 to 1.38)
Model 2
0.55 (-0.23 to 1.33)
0.61 (-0.14 to 1.35)
Model 3
0.46 (-0.30 to 1.23)
0.57 (-0.20 to 1.34)
MVPA ≥10 minute bouts (per 5 minutes higher)
Model 1
1.68 (-0.01 to 3.37)
2.25 (-1.55 to 6.06)
Model 2
1.67 (-0.03 to 3.37)
2.09 (-1.83 to 6.01)
Model 3
1.14 (-0.58 to 2.86)
2.70 (-1.30 to 6.70)
Number of sedentary breaks (No. of breaks/day)
Model 1
-0.01 (-0.09 to 0.06)
0.08 (0.00 to 0.15)
Model 2
-0.01 (-0.09 to 0.07)
0.08 (0.00 to 0.15)
Model 3
-0.01 (-0.09 to 0.06)
-0.01 (-0.01 to 0.15)
ASTP (per 0.1 ASTP)
Model 1
-0.31 (-1.74 to 1.13)
-0.49 (-1.46 to 0.47)
Model 2
-0.37 (-1.82 to 1.08)
-0.42 (-1.43 to 0.58)
Model 3
-0.33 (-1.78 to 1.12)
-0.33 (-1.28 to 0.87)
Notes: Bold values are significant. The active-to-sedentary transition probability index is calculated by
dividing the total number of breaks in sedentary behavior with the sum of minutes spent in physical
activity.
Abbreviations: ASTP: active-to-sedentary transition probability; ß (95% CI): Beta coefficient (95%
confidence interval); MVPA: moderate to vigorous physical activity.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease,
history of cancer)

4.1.4 Dose-Response Associations of Physical Behavior Metrics with Probable
Sarcopenia
Volumes: Dose-response associations of physical behavior volume metrics with
the odds of probable sarcopenia specified by EWGSOP2 are presented in Table 15.
Participants who accumulated at least 10 minutes of total MVPA had 26% (95% CI 0.62
to 0.89) lower odds of probable sarcopenia compared to the reference group of
participants accumulating less than 5 minutes per day of total MVPA volumes in the fully
adjusted model. There were no significant associations across tertiles of total activity
counts, LIPA, and SB with probable sarcopenia.
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Table 15: Dose-response associations of physical behavior volume metrics with
probable sarcopenia
Dose-response associations of TAC tertiles with probable sarcopenia
Total TAC (mean/SD)
First Tertile
Second Tertile
n
49
48
TAC, mean (SD)
144,307 (43,221)
232,572 (21,296)
Probable sarcopenia (yes/no)
Model 1
Ref
1.02 (0.84 to 1.24)
Model 2
Ref
1.01 (0.84 to 1.23)
Model 3
Ref
1.01 (0.83 to 1.23)
Dose-response associations of total MVPA groups with probable sarcopenia
Total MVPA (min/day)
0-5 min Group
5-10 min Group
n
67
34
MVPA, mean (SD)
2.7 (1.1)
7.1 (1.4)
Probable sarcopenia (yes/no)
Model 1
Ref
0.91 (0.76 to 1.11)
Model 2
Ref
0.92 (0.76 to 1.11)
Model 3
Ref
0.91 (0.75 to 1.12)
Dose-response associations of total LIPA tertiles with probable sarcopenia
Total LIPA (min/day)
First Tertile
Second Tertile
n
49
48
LIPA, mean (SD)
92.2 (29.3)
148.7 (13.4)
Probable sarcopenia (yes/no)
Model 1
Ref
0.96 (0.80 to 1.17)
Model 2
Ref
0.96 (0.80 to 1.17)
Model 3
Ref
0.97 (0.80 to 1.18)

Third Tertile
48
357,901 (85,911)
0.90 (0.74 to 1.10)
0.89 (0.73 to 1.09)
0.88 (0.71 to 1.08)

≥10 min Group
44
21.9 (11.1)
0.73 (0.61 to 0.88)
0.74 (0.62 to 0.89)
0.74 (0.62 to 0.89)

Third Tertile
48
214.3 (42.5)
0.90 (0.74 to 1.09)
0.91 (0.75 to 1.11)
0.91 (0.74 to 1.11)

Dose-response associations of total SB tertiles with probable sarcopenia
Total SB (min/day)
First Tertile
Second Tertile
Third Tertile
n
49
48
48
SB, mean (SD)
577.4 (54.1)
662.7 (21.6)
822.0 (122.3)
Probable sarcopenia (yes/no)
Model 1
Ref
1.02 (0.83 to 1.24)
1.20 (0.93 to 1.53)
Model 2
Ref
1.03 (0.84 to 1.26)
1.21 (0.94 to 1.55)
Model 3
Ref
1.02 (0.83 to 1.25)
1.21 (0.94 to 1.57)
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg
for women).
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity; OR
(95% CI): odds ratio (95% confidence interval); Ref: Reference; SB: sedentary behavior; TAC: Total activity
counts.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease,
history of cancer)
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Patterns: Table 16 illustrates dose-response associations of physical behavior
pattern metrics with the odds of probable sarcopenia defined by EWGSOP2 in the
primary sample. The highest tertile of accumulated minutes in short MVPA bouts of less
than 10 minutes also demonstrated a 22% (95% CI 0.64 to 0.95) lower likelihood for
probable sarcopenia, compared to the lowest tertile of short MVPA bouts (<10 minutes)
following final adjustment. Likewise, the odds of probable sarcopenia were 22% (95% CI
0.63 to 0.98, model 3) lower among participants who had any minutes spent in long
MVPA bouts of at least 10 minutes compared to participants who had zero accumulated
time in long MVPA bouts (≥10 minutes). The study results also indicated no significant
associations across tertiles of sedentary breaks and ASTP with probable sarcopenic
status.
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Table 16: Dose-response associations of physical behavior pattern metrics with
probable sarcopenia
Dose-response associations of short MVPA bouts (<10 minutes) duration tertiles with probable sarcopenia
MVPA <10 minute bout (min/day)
First Tertile
Second Tertile
Third Tertile
n
49
48
48
MVPA <10 minute bout, mean (SD)
2.2 (0.9)
5.6 (9.5)
17.8 (9.8)
Probable sarcopenia (yes/no)
Model 1
Ref
0.90 (0.75 to 1.09)
0.77 (0.63 to 0.93)
Model 2
Ref
0.89 (0.74 to 1.08)
0.77 (0.64 to 0.94)
Model 3
Ref
0.89 (0.74 to 1.08)
0.78 (0.64 to 0.95)
Dose-response associations of long MVPA bouts (≥10 minutes) duration groups with probable sarcopenia
MVPA ≥10 minute bout (min/day)
No ≥10 minute bouts
≥10 minute bouts
n
124
21
MVPA ≥10 minute bout, mean (SD)
0.0 (0.0)
7.3 (5.3)
Probable sarcopenia (yes/no)
Model 1
Ref
0.77 (0.62 to 0.96)
Model 2
Ref
0.78 (0.62 to 0.97)
Model 3
Ref
0.78 (0.63 to 0.98)
Dose-response associations of number of sedentary breaks tertiles with probable sarcopenia
Number of sedentary breaks (no. of breaks/day)
First Tertile
Second Tertile
Third Tertile
n
49
48
48
Sedentary breaks, mean (SD)
50.4 (12.4)
70.2 (3.8)
88.2 (13.4)
Probable sarcopenia (yes/no)
Model 1
Ref
1.04 (0.86 to 1.26)
0.92 (0.76 to 1.13)
Model 2
Ref
1.04 (0.86 to 1.26)
0.92 (0.75 to 1.12)
Model 3
Ref
1.03 (0.85 to 1.26)
0.91 (0.74 to 1.12)
Dose-response associations of ASTP tertiles with probable sarcopenia
First Tertile
49
0.35 (0.05)

ASTP
Second Tertile
48
0.47 (0.03)

Third Tertile
48
0.59 (0.07)

n
ASTP, mean (SD)
Probable sarcopenia (yes/no)
Model 1
Ref
1.15 (0.94 to 1.40)
1.21 (1.00 to 1.47)
Model 2
Ref
1.14 (0.94 to 1.38)
1.19 (0.98 to 1.45)
Model 3
Ref
1.14 (0.93 to 1.40)
1.18 (0.97 to 1.44)
Notes: Bold values are significant. Probable sarcopenia is defined using low upper limb muscle strength
evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg for women). The
active-to-sedentary transition probability index is calculated by dividing the total number of breaks in sedentary
behavior with the sum of minutes spent in physical activity.
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous physical activity;
OR (95% CI): odds ratio (95% confidence interval); Ref: Reference.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, history
of cancer)
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4.2 Subsample
4.2.1. Participant Characteristics
The subsample included 87 participants with valid measurements of handgrip
strength, DXA scans, gait speed, and accelerometry. Among them, 28 (32.2%) were
classified as probable sarcopenic, 18 (20.7%) as confirmed sarcopenic, and 8 (9.2%) as
severe sarcopenic according to the EWGSOP2 definition. The demographic and lifestyle
factors of our subsample revealed mean values or frequencies similar to the primary
sample. On average, participants in the subsample spent 9.1 (10.7) minutes per day or
1.1% (1.2%) of the accelerometer wear time in MVPA, 148.4 (54.0) minutes per day or
17.9% (6.9%) in LIPA, and 684.3 (139.4) minutes per day or 81.0% (7.7%) in SB. The
mean of sarcopenia-relevant metrics, including handgrip strength (men: 29.2 (6.6) kg,
women: 18.4 (5.5) kg), appendicular lean mass (men: 21.6 (2.7) kg, women: 15.3 (2.9)
kg), and gait speed (0.96 (0.24) m/s), are reported in Table 17.
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Table 17: Participant characteristics of the subsample
Total sample
(n = 87)

Nonsarcopenic
(n = 59)

Probable sarcopenic
(n = 28)

Confirmed sarcopenic
(n = 18)

Severe sarcopenic
(n = 8)

88.2 (2.5)
48 (55.2%)
27 (31.0%)
53 (60.9%)
87 (100.0%)

88.2 (2.8)
34 (57.6%)
23 (39.0%)
34 (57.6%)
59 (100.0%)

88.4 (2.0)
14 (50.0%)
4 (14.3%)
19 (67.9%)
28 (100.0%)

87.9 (2.1)
11 (61.1%)
3 (16.7%)
14 (77.8%)
18 (100.0%)

87.9 (1.6)
5 (62.5%)
2 (25.0%)
6 (75.0%)
8 (100.0%)

Lifestyle factors
BMI (kg/m2), mean (SD)
Current smoker, n (%)

26.6 (4.3)
4 (4.6%)

27.3 (4.6)
2 (3.4%)

25.2 (3.3)
2 (7.1%)

24.1 (3.2)
2 (11.1%)

24.4 (3.6)
1 (12.5%)

Chronic health conditions
Diabetes, n (%)
Hypertension, n (%)
History of cardiovascular disease, n (%)
History of cancer, n (%)

20 (23.0%)
63 (72.4%)
28 (32.2%)
27 (31.0%)

13 (22.0%)
41 (69.5%)
19 (32.2%)
20 (33.9%)

7 (25.0%)
22 (78.6%)
9 (32.1%)
7 (25.0%)

5 (27.8%)
15 (83.3%)
5 (27.8%)
3 (16.7%)

3 (37.5%)
8 (100.0%)
4 (50.0%)
2 (25.0%)

23.3 (8.0)
29.2 (6.6)

26.1 (7.2)
33.1 (4.2)

17.2 (6.0)
22.3 (3.3)

15.8 (6.2)
22.1 (3.9)

16.9 (5.5)
22.8 (3.0)

18.4 (5.5)

21.0 (3.9)

12.1 (3.0)

11.8 (3.3)

13.3 (2.4)

34.8 (6.7)

35.1 (6.9)

34.3 (6.2)

35.9 (5.5)

36.2 (4.4)

18.1 (4.2)

18.8 (4.1)

16.7 (4.0)

14.9 (3.2)

15.0 (3.2)

21.6 (2.7)

22.4 (2.8)

20.2 (2.0)

18.6 (0.9)

18.7 (0.9)

Demographic factors
Age, years, mean (SD)
Women, n (%)
Race, n (%), black
Education, n (%), postsecondary
Site, n (%), Memphis

Muscle strength
Handgrip strength (kg), mean (SD)
Handgrip strength men (kg), mean (SD)
Handgrip strength women (kg), mean
(SD)
DXA-acquired body composition
measures
Total body fat (%), mean (SD)
Appendicular lean mass (kg),
mean (SD)
Appendicular lean mass men (kg),
mean (SD)
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Appendicular lean mass women (kg),
mean (SD)
Physical performance
Gait speed (m/s), mean (SD)

15.3 (2.9)

16.2 (2.8)

13.2 (1.8)

12.5 (1.1)

12.7 (0.5)

0.96 (0.24)

1.00 (0.24)

0.90 (0.23)

0.85 (0.23)

0.63 (0.10)

Accelerometer
Average minutes of weartime
841.8 (126.7)
840.2 (124.2)
845.3 (134.1)
835.1 (101.0)
814.1 (110.4)
(min/day), mean (SD)
245,687 (109,216)
248,125 (115,022)
240,549 (97,635)
225,578 (96,781)
203,376 (137,803)
TAC (counts/day), mean (SD)
0.6 (0.3, 1.1)
0.7 (0.4, 1.7)
0.4 (0.3, 1.0)
0.4 (0.1, 0.8)
0.3 (0.2, 0.4)
% time MVPA, median (IQR)
1.1
(1.2)
1.2
(1.3)
0.8
(1.1)
0.6
(0.5)
0.4 (0.3)
% time MVPA, mean (SD)
17.9 (6.9)
18.5 (7.2)
16.7 (6.2)
14.9 (5.5)
12.9 (5.7)
% LIPA, mean (SD)
81.0 (7.7)
80.2 (8.1)
82.5 (6.8)
84.5 (5.7)
86.7 (5.8)
% SB, mean (SD)
4.9 (3.0, 11.3)
5.2 (3.2, 14.9)
3.4 (2.8, 7.4)
3.5 (3.0, 6.8)
3.0 (1.7, 3.5)
MVPA (min/day), median (IQR)
9.1 (10.7)
10.3 (11.2)
6.6 (9.2)
4.9 (3.6)
3.0 (2.0)
MVPA (min/day), mean (SD)
148.4 (54.0)
153.0 (57.0)
138.6 (46.5)
123.1 (41.2)
104.7 (45.8)
LIPA (min/day), mean (SD)
684.3 (139.4)
676.9 (139.8)
700.0 (139.8)
707.2 (106.8)
706.4 (110.5)
SB (min/day), mean (SD)
MVPA in bouts <10 min (min/day),
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
median (IQR)
MVPA in bouts <10 min (min/day),
8.0 (8.7)
8.7 (8.5)
6.6 (9.2)
4.9 (3.6)
3.0 (2.0)
mean (SD)
MVPA in bouts ≥10 min (min/day),
4.9 (3.0, 9.6)
5.2 (3.2, 12.3)
3.4 (2.8, 7.4)
3.5 (3.0, 6.8)
3.0 (1.7, 3.5)
median (IQR)
MVPA in bouts ≥10 min (min/day),
1.1 (3.7)
1.6 (4.4)
0.0 (0.0)
0.0 (0.0)
0.0 (0.0)
mean (SD)
Number of sedentary breaks
70.4 (17.0)
70.9 (17.2)
69.4 (16.9)
63.9 (15.9)
60.1 (20.8)
(No. of breaks/day), mean (SD)
0.48 (0.12)
0.48 (0.13)
0.50 (0.09)
0.52 (0.09)
0.58 (0.08)
ASTP, mean (SD)
Notes: All data are mean +/- SD (independent samples t tests), except median (interquartile range) (Mann-Whitney U-tests) and proportions (chi-square test). The active-tosedentary transition probability index is calculated by dividing the total number of breaks in sedentary behavior with the sum of minutes spent in physical activity.
Abbreviations: ASTP: active-to-sedentary transition probability; BMI: body mass index; LIPA: light intensity physical activity; MVPA: moderate to vigorous physical
activity; SB: sedentary behavior; TAC: Total activity counts.
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4.2.2 Associations of Physical Behavior Metrics with Sarcopenia Status (Binomial
Logistic Regressions)
Volumes: Table 18 demonstrates the odds ratios for the associations of physical
behavior volume metrics with any sarcopenic status according to the EWGSOP2
definition, including probable sarcopenia, confirmed sarcopenia, and severe sarcopenia,
in the subsample.
Probable sarcopenia: There were no significant associations of any physical
behavior volume metric with probable sarcopenia.
Confirmed sarcopenia: Each 5 minutes per day of MVPA higher was associated
with a 49% (95% CI 0.26 to 0.98) lower likelihood for confirmed sarcopenia after
adjusting for age, gender, race, education, and accelerometer wear time (model 1).
Similarly, each 60 minutes higher of daily LIPA was associated with 55% (95% CI 0.22
to 0.89) lower odds of confirmed sarcopenia in the same model (model 1). However, the
associations of LIPA and MVPA with confirmed sarcopenia were attenuated and thus no
longer significant after further adjusting for lifestyle factors (model 2) and chronic health
conditions (model 3). Furthermore, each additional 60 minutes per day of SB volume was
associated with 2.1 (95% CI 1.01 to 4.35) times higher odds of confirmed sarcopenia
after full adjustment. No significant association was observed between total activity
counts and confirmed sarcopenia.
Severe sarcopenia: The odds for a severe sarcopenia diagnosis were 68% (95% CI
0.11 to 0.91, model 2) lower following each 60 minutes more per day of LIPA but did not
remain significant after full adjustment (model 3). Each additional 60 minutes per day
spent in SB was associated with 3.18 (95% CI 1.13 to 8.92, model 2) times higher odds
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of severe sarcopenia. However, the significance of this relationship was also attenuated
and therefore no longer significant after adjusting for chronic health conditions (model
3). In addition, there were no significant associations of total activity counts and MVPA
with severe sarcopenia.
Table 18: Odds ratios for the associations of physical behavior volume metrics with
sarcopenia status
Probable sarcopenic
OR (95 % CI)

Dichotomous (yes/no)
Confirmed sarcopenic
OR (95% CI)

Severe sarcopenic
OR (95% CI)

Physical behavior volumes
TAC (per 1 SD (109,216 counts))
Model 1
0.84 (0.51 to 1.38)
0.65 (0.34 to 1.24)
0.54 (0.21 to 1.43)
Model 2
0.82 (0.49 to 1.36)
0.64 (0.33 to 1.26)
0.53 (0.19 to 1.47)
Model 3
0.85 (0.49 to 1.46)
0.57 (0.27 to 1.21)
0.54 (0.17 to 1.70)
Total MVPA (per 5 minutes higher)
Model 1
0.74 (0.54 to 1.02)
0.51 (0.26 to 0.98)
0.10 (0.01 to 1.13)
Model 2
0.75 (0.54 to 1.02)
0.52 (0.26 to 1.02)
0.06 (0.00 to 1.10)
Model 3
0.75 (0.54 to 1.05)
0.48 (0.23 to 1.00)
0.02 (0.00 to 1.17)
Total LIPA (per 60 minutes higher)
Model 1
0.77 (0.45 to 1.32)
0.45 (0.22 to 0.89)
0.30 (0.11 to 0.82)
Model 2
0.83 (0.48 to 1.43)
0.50 (0.24 to 1.03)
0.32 (0.11 to 0.91)
Model 3
0.89 (0.49 to 1.58)
0.47 (0.21 to 1.04)
0.27 (0.07 to 1.07)
Total SB (per 60 minutes higher)
Model 1
1.35 (0.82 to 2.20)
2.19 (1.15 to 4.18)
3.23 (1.23 to 8.47)
Model 2
1.27 (0.77 to 2.08)
1.99 (1.01 to 3.89)
3.18 (1.13 to 8.92)
Model 3
1.20 (0.71 to 2.02)
2.10 (1.01 to 4.35)
3.79 (0.99 to 14.56)
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg
for women), low muscle mass tested by a dual-energy X-ray absorptiometry (appendicular skeletal muscle
mass: <20 kg for men and <15 kg for women), and low physical performance assessed by a 20-m usual
walking speed test (gait speed: ≤0.8 m/s).
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity; OR
(95% CI): odds ratio (95% confidence interval); SB: sedentary behavior; TAC: Total activity counts.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease,
history of cancer)

Patterns: Table 19 shows the odds ratios for the associations of physical behavior
pattern metrics with any sarcopenic status according to the EWGSOP2 definition,
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including probable sarcopenia, confirmed sarcopenia, and severe sarcopenia, in the
subsample.
Probable sarcopenia: All physical behavior pattern metrics, including short
MVPA bouts (<10 minutes), long MVPA bouts (≥10 minutes), total number of sedentary
breaks, and ASTP, showed non-significant associations with probable sarcopenia.
Confirmed sarcopenia: There were no significant associations of any physical
behavior pattern metric with confirmed sarcopenia.
Severe sarcopenia: Each 0.1 ASTP higher was associated with 2.9 (95% CI 1.05
to 8.02) times higher odds of severe sarcopenia in the fully adjusted model 3. Other PA
pattern metrics, including short MVPA bouts (<10 minutes), long MVPA bouts (≥10
minutes), and sedentary breaks, were not associated with severe sarcopenia.
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Table 19: Odds ratios for the associations of physical behavior pattern metrics with
sarcopenia status
Probable sarcopenic
OR (95 % CI)

Dichotomous (yes/no)
Confirmed sarcopenic
OR (95% CI)

Severe sarcopenic
OR (95% CI)

Physical behavior patterns
MVPA <10 minute bouts (per 5 minutes higher)
Model 1
0.80 (0.57 to 1.12)
0.49 (0.24 to 1.00)
0.09 (0.01 to 1.02)
Model 2
0.80 (0.57 to 1.11)
0.51 (0.25 to 1.05)
0.05 (0.00 to 1.00)
Model 3
0.81 (0.57 to 1.15)
0.47 (0.22 to 1.01)
0.02 (0.00 to 1.09)
MVPA ≥10 minute bouts (per 5 minutes higher)
Model 1
N/A
N/A
N/A
Model 2
N/A
N/A
N/A
Model 3
N/A
N/A
N/A
Number of sedentary breaks (No. of breaks/day)
Model 1
1.00 (0.97 to 1.03)
0.97 (0.94 to 1.00)
0.96 (0.92 to 1.01)
Model 2
1.00 (0.97 to 1.03)
0.97 (0.94 to 1.01)
0.96 (0.92 to 1.01)
Model 3
1.01 (0.97 to 1.04)
0.97 (0.93 to 1.01)
0.96 (0.91 to 1.02)
ASTP (per 0.1 ASTP)
Model 1
1.27 (0.84 to 1.91)
1.51 (0.94 to 2.43)
2.30 (1.17 to 4.50)
Model 2
1.23 (0.81 to 1.87)
1.50 (0.89 to 2.50)
2.47 (1.19 to 5.15)
Model 3
1.16 (0.75 to 1.80)
1.43 (0.82 to 2.48)
2.90 (1.05 to 8.02)
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg for
women), low muscle mass tested by a dual-energy X-ray absorptiometry (appendicular skeletal muscle mass:
<20 kg for men and <15 kg for women), and low physical performance assessed by a 20-m usual walking speed
test (gait speed: ≤0.8 m/s). The active-to-sedentary transition probability index is calculated by dividing the
total number of breaks in sedentary behavior with the sum of minutes spent in physical activity.
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous physical
activity; OR (95% CI): odds ratio (95% confidence interval).
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, history
of cancer)

4.2.3 Associations of Physical Behavior Metrics with Sarcopenia-Relevant
Components (Multivariate Linear Regressions by Gender)
Volumes: Table 20 illustrates multivariate linear regression outcomes by gender
of the subsample on associations of physical behavior volume metrics with sarcopeniarelated parameters including handgrip strength, appendicular lean mass, and gait speed.
Handgrip strength: There were no significant associations of handgrip strength
with any physical behavior volume metric in the subsample.
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Appendicular lean mass: Among women, each 60 minutes per day higher SB was
associated with lower appendicular lean mass (ß=-0.66, 95% CI -1.31 to -0.01) after
adjusting for age, gender, race, education, and accelerometer wear time (model 1) but did
not remain significant after further adjustments for lifestyle factors (model 2) and chronic
health conditions (model 3). Total activity counts, LIPA, and MVPA were not associated
with appendicular lean mass in women. Men demonstrated non-significant associations
across all physical behavior volume metrics, including total activity counts, MVPA,
LIPA, and SB, with appendicular lean mass.
Gait speed: Gait speed was significantly better among men for each SD (109,216
counts) higher total activity counts (ß=0.09, 95% CI 0.01 to 0.17), each 5 minutes higher
MVPA (ß=0.03, 95% CI 0.01 to 0.06), and each 60 minutes higher LIPA (ß=0.15, 95%
CI 0.06 to 0.24) across all models. Higher volumes of SB demonstrated a non-significant
association with gait speed in men. Among women, higher total activity counts per 1 SD
(109,216 counts) showed associations with better gait speed in model 2 (ß=0.07, 95% CI
0.01 to 0.14) but lacked significance in model 3. Likewise, each 60 minutes more in
LIPA was associated with higher gait speed (ß=0.12, 95% CI 0.05 to 0.18, model 2) and
every 60 minutes more in SB was associated with lower gait speed (ß=-0.10, 95% CI 0.16 to -0.04, model 2) in women but did not remain significant after full adjustment.
Total volumes of MVPA were not associated with gait speed among women.
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Table 20: Linear regression associations of physical behavior volume metrics with sarcopenia-relevant components by gender
Handgrip strength (kg)
ß (95% CI)
Men (n = 39)

Women (n = 48)

Appendicular lean mass (kg)
ß (95% CI)
Men (n = 39)

Women (n = 48)

Gait speed (m/s)
ß (95% CI)
Men (n = 39)

Women (n = 48)

Physical behavior volumes
TAC (per 1 SD (109,216 counts))
Model 1
0.64 (-1.64 to 2.91)
0.33 (-1.23 to 1.90)
0.08 (-0.86 to 1.02)
0.36 (-0.37 to 1.08)
0.09 (0.02 to 0.16)
0.07 (0.01 to 0.14)
Model 2
0.71 (-1.63 to 3.05)
0.34 (-1.15 to 1.82)
0.36 (-0.45 to 1.16)
0.36 (-0.18 to 0.90)
0.09 (0.02 to 0.16)
0.07 (0.01 to 0.14)
Model 3
0.03 (-2.30 to 2.35)
-0.26 (-1.93 to 1.41)
0.17 (-0.65 to 0.99)
0.33 (-0.30 to 0.95)
0.09 (0.01 to 0.17)
0.03 (-0.04 to 0.10)
Total MVPA (per 5 minutes higher)
Model 1
0.59 (-0.22 to 1.41)
0.53 (-0.61 to 1.68)
-0.04 (-0.39 to 0.30)
0.24 (-0.30 to 0.77)
0.03 (0.01 to 0.06)
0.04 (-0.01 to 0.09)
Model 2
0.60 (-0.22 to 1.43)
0.34 (-0.76 to 1.44)
-0.01 (-0.31 to 0.28)
0.07 (-0.34 to 0.48)
0.03 (0.01 to 0.06)
0.04 (-0.01 to 0.09)
Model 3
0.36 (-0.46 to 1.19)
0.13 (-1.07 to 1.34)
-0.04 (-0.34 to 0.25)
0.03 (-0.43 to 0.49)
0.03 (0.01 to 0.06)
0.01 (-0.04 to 0.06)
Total LIPA (per 60 minutes higher)
Model 1
-0.12 (-2.93 to 2.69)
0.92 (-0.64 to 2.48)
0.03 (-1.13 to 1.18)
0.75 (0.04 to 1.45)
0.13 (0.04 to 0.21)
0.11 (0.05 to 0.17)
Model 2
-0.08 (-2.95 to 2.79)
0.50 (-1.04 to 2.04)
0.25 (-0.74 to 1.24)
0.39 (-0.17 to 0.95)
0.13 (0.04 to 0.21)
0.12 (0.05 to 0.18)
Model 3
-0.81 (-3.96 to 2.06) -0.10 (-1.90 to 1.71)
0.35 (-0.66 to 1.37)
0.37 (-0.31 to 1.05)
0.15 (0.06 to 0.24)
0.07 (0.00 to 0.15)
Total SB (per 60 minutes higher)
Model 1
-0.31 (-2.65 to 2.04) -0.84 (-2.27 to 0.58)
0.01 (-0.96 to 0.97)
-0.66 (-1.31 to -0.01)
-0.11 (-0.18 to 0.04) -0.10 (-0.16 to -0.04)
Model 2
-0.34 (-2.73 to 2.05) -0.46 (-1.87 to 0.95)
-0.16 (-0.99 to 0.66)
-0.33 (-0.85 to 0.18)
-0.11 (-0.18 to 0.04) -0.10 (-0.16 to -0.04)
Model 3
0.31 (-2.09 to 2.71)
0.06 (-1.59 to 1.71)
-0.21 (-1.06 to 0.63)
-0.31 (-0.93 to 0.31)
-0.13 (-0.20 to 0.05)
-0.06 (-0.13 to 0.00)
Notes: Bold values are significant.
Abbreviations: ß (95% CI): Beta coefficient (95% confidence interval); LIPA: light intensity physical activity; MVPA: moderate to vigorous physical activity; SB: sedentary
behavior; TAC: Total activity counts.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, history of cancer)
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Patterns: Table 21 depicts multivariate linear regression outcomes by gender of
the subsample on associations of physical behavior pattern metrics with sarcopeniarelated indicators including handgrip strength, appendicular lean mass, and gait speed.
Handgrip strength: There were no significant associations of handgrip strength
with any physical behavior pattern metric in the subsample.
Appendicular lean mass: A higher number of sedentary breaks was associated
with higher appendicular lean mass (ß=0.05, 95% CI 0.01 to 0.09) among women in the
fully adjusted model. There were no significant associations of short MVPA bouts (<10
minutes), long MVPA bouts (≥10 minutes), and ASTP with appendicular lean mass in
women. On the other hand, all analyzed PA pattern metrics, including short MVPA bouts
(<10-minutes), long MVPA bouts (≥10 minutes), sedentary breaks, and ASTP, showed
non-significant associations with appendicular lean mass among men.
Gait speed: Each additional 5 minutes spent in short MVPA bouts (<10 minutes)
among men was associated with faster gait speed in model 2 (ß=0.04, 95% CI 0.01 to
0.07) but attenuated after final adjustment. No relationship was observed between higher
levels of short MVPA bouts (<10 minutes) and gait speed among women. Furthermore,
men and women significantly lowered gait speed per each added 0.1 ASTP (men: ß=0.14, 95% CI -0.20 to -0.08, women: ß=-0.07, 95% CI -0.12 to -0.02) in the fully adjusted
model. On the other hand, long MVPA bouts (≥10 minutes) and sedentary breaks were
not associated with gait speed in men and women.
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Table 21: Linear regression associations of physical behavior pattern metrics with sarcopenia-relevant components by gender
Handgrip strength (kg)
ß (95% CI)

Appendicular lean mass (kg)
ß (95% CI)

Gait speed (m/s)
ß (95% CI)

Men (n = 39)
Women (n = 48)
Men (n = 39)
Women (n = 48)
Men (n = 39)
Women (n = 48)
Physical behavior patterns
MVPA <10 minute bouts (per 5 minutes higher)
Model 1
0.51 (-0.52 to 1.54)
0.56 (-0.62 to 1.74)
-0.04 (-0.47 to 0.39)
0.23 (-0.33 to 0.78)
0.04 (0.01 to 0.07)
0.05 (0.00 to 0.10)
Model 2
0.54 (-0.52 to 1.59)
0.44 (-0.68 to 1.57)
0.06 (-0.31 to 0.43)
0.12 (-0.29 to 0.54)
0.04 (0.01 to 0.07)
0.05 (0.00 to 0.11)
Model 3
0.30 (-0.73 to 1.34)
0.19 (-1.06 to 1.45)
0.01 (-0.36 to 0.38)
0.08 (-0.40 to 0.56)
0.00 (0.00 to 0.08)
0.02 (-0.03 to 0.07)
MVPA ≥10 minute bouts (per 5 minutes higher)
Model 1
N/A
N/A
N/A
N/A
N/A
N/A
Model 2
N/A
N/A
N/A
N/A
N/A
N/A
Model 3
N/A
N/A
N/A
N/A
N/A
N/A
Number of sedentary breaks (No. of breaks/day)
Model 1
-0.07 (-0.21 to 0.06)
0.07 (-0.03 to 0.16)
0.01 (-0.05 to 0.07)
0.07 (0.03 to 0.11)
0.00 (0.00 to 0.01)
0.01 (0.00 to 0.01)
Model 2
-0.07 (-0.21 to 0.07)
0.04 (-0.05 to 0.13)
0.02 (-0.03 to 0.07)
0.05 (0.02 to 0.08)
0.00 (0.00 to 0.01)
0.01 (0.00 to 0.01)
Model 3
-0.10 (-0.23 to 0.04)
0.01 (-0.10 to 0.11)
0.02 (-0.03 to 0.07)
0.05 (0.01 to 0.09)
0.00 (0.00 to 0.01)
0.00 (0.00 to 0.01)
ASTP (per 0.1 ASTP)
Model 1
-0.02 (-2.13 to 2.09)
-0.60 (-1.86 to 0.65)
0.35 (-0.51 to 1.21)
-0.39 (-0.97 to 0.19)
-0.12 (-0.17 to -0.06)
-0.10 (-0.14 to -0.05)
Model 2
-0.04 (-2.19 to 2.10)
-0.36 (-1.58 to 0.86)
0.23 (-0.51 to 0.97)
-0.18 (-0.63 to 0.27)
-0.12 (-0.18 to -0.06)
-0.10 (-0.15 to -0.05)
Model 3
0.46 (-1.72 to 2.64)
-0.00 (-1.37 to 1.36)
0.06 (-0.72 to 0.83)
-0.17 (-0.69 to 0.35)
-0.14 (-0.20 to -0.08)
-0.07 (-0.12 to -0.02)
Notes: Bold values are significant. The active-to-sedentary transition probability index is calculated by dividing the total number of breaks in sedentary behavior with the sum of
minutes spent in physical activity.
Abbreviations: ß (95% CI): ASTP: active-to-sedentary transition probability; Beta coefficient (95% confidence interval); MVPA: moderate to vigorous physical activity; N/A:
Not available.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease, history of cancer)
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4.2.4 Dose-Response Associations of Physical Behavior Metrics with Sarcopenia
Status
Volumes: The outcomes of the subsample regarding the dose-response
associations of physical behavior volume metrics with EWGSOP2 defined sarcopenic
status, including probable sarcopenia, confirmed sarcopenia, and severe sarcopenia, are
illustrated in Table 22.
Probable sarcopenia: In contrast to individuals who provided 0-5 minutes per day
of total volume of MVPA, participants with at least 10 minutes per day of total MVPA
showed significant lower odds of probable sarcopenia (OR=0.77, 95% CI 0.61 to 0.98,
model 2). There were no significant associations across tertiles of total activity counts,
LIPA, and SB with probable sarcopenia.
Confirmed sarcopenia: Participants in the highest tertile of total activity counts
had significantly lower odds of confirmed sarcopenia (OR=0.81, 95% CI 0.66 to 0.99,
model 2) when compared to participants in the lowest tertile. Model 1 and model 3
presented non-significant results of this association. The likelihood for a confirmed
sarcopenia diagnosis was significantly lower among participants who spent at least 10
minutes per day in total volumes of MVPA (OR=0.79, 95% CI 0.65 to 0.97, model 2)
compared to the group of individuals who engaged in less than 5 minutes per day of total
MVPA. Similarly, participants in the highest tertile of LIPA had significantly lower odds
of confirmed sarcopenia (OR=0.80, 95% CI 0.66 to 0.98, model 2) when compared to the
lowest tertile of LIPA. However, after adjusting for chronic health conditions (model 3),
the associations of MVPA and LIPA with confirmed sarcopenia were no longer
significant. In comparison to individuals among the lowest tertile of SB (least sedentary
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group), participants in the highest tertile of SB (most sedentary group) indicated 1.41
(95% CI 0.91 to 1.41) higher odds of confirmed sarcopenia in the fully adjusted model.
Severe sarcopenia: Individuals among the highest tertile of total activity counts
had a significantly lower likelihood for severe sarcopenia (OR=0.85, 95% CI 0.73 to
0.99) in contrast to participants among the lowest tertile of total activity counts. Model 1
and model 3, however, demonstrated non-significant results of this association. The odds
for severe sarcopenia were significantly lower among participants who spent 10 minutes
or more per day in total MVPA (OR=0.85, 95% CI 0.73 to 0.99, model 2) compared to
individuals with less than 5 minutes per day of total MVPA. Participants in the highest
tertile of LIPA also demonstrated a significant association with severe sarcopenia
(OR=0.85, 95% CI 0.73 to 0.99, model 2) when compared with participants among the
lowest tertile of LIPA. The adjustment for comorbid conditions (model 3), however,
attenuated the significance regarding the associations of MVPA and LIPA with severe
sarcopenia. No significant associations were observed across tertiles of SB with severe
sarcopenia.
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Table 22: Dose-response associations of physical behavior volume metrics with
sarcopenia status
Dose-response associations of TAC tertiles with sarcopenia status
Total TAC (mean/SD)
First Tertile
Second Tertile
n
29
29
TAC, mean (SD)
145,877 (44,216)
226,888 (21,107)
Probable sarcopenia (yes/no)
Model 1
Ref
1.01 (0.79 to 1.29)
Model 2
Ref
0.98 (0.77 to 1.25)
Model 3
Ref
0.98 (0.77 to 1.26)
Confirmed sarcopenia (yes/no)
Model 1
Ref
0.99 (0.80 to 1.23)
Model 2
Ref
0.95 (0.77 to 1.16)
Model 3
Ref
0.95 (0.78 to 1.16)
Severe sarcopenia (yes/no)
Model 1
Ref
0.88 (0.76 to 1.03)
Model 2
Ref
0.86 (0.74 to 1.01)
Model 3
Ref
0.86 (0.74 to 1.01)
Dose-response associations of total MVPA groups with sarcopenia status
Total MVPA (min/day)
0-5 min Group
5-10 min Group
n
45
18
MVPA, mean (SD)
2.8 (1.0)
7.0 (1.5)
Probable sarcopenia (yes/no)
Model 1
Ref
0.89 (0.69 to 1.16)
Model 2
Ref
0.90 (0.69 to 1.16)
Model 3
Ref
0.89 (0.68 to 1.15)
Confirmed sarcopenia (yes/no)
Model 1
Ref
0.98 (0.78 to 1.22)
Model 2
Ref
0.98 (0.79 to 1.21)
Model 3
Ref
0.96 (0.77 to 1.19)
Severe sarcopenia (yes/no)
Model 1
Ref
0.88 (0.75 to 1.03)
Model 2
Ref
0.88 (0.74 to 1.03)
Model 3
Ref
0.87 (0.74 to 1.03)
Dose-response associations of total LIPA tertiles with sarcopenia status
Total LIPA (min/day)
First Tertile
Second Tertile
n
29
29
LIPA, mean (SD)
92.3 (30.2)
147.6 (11.7)
Probable sarcopenia (yes/no)
Model 1
Ref
0.91 (0.71 to 1.16)
Model 2
Ref
0.90 (0.71 to 1.15)
Model 3
Ref
0.92 (0.72 to 1.18)
Confirmed sarcopenia (yes/no)
Model 1
Ref
0.94 (0.76 to 1.15)
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Third Tertile
29
364,295 (94,771)
0.85 (0.66 to 1.09)
0.83 (0.65 to 1.06)
0.84 (0.66 to 1.08)
0.83 (0.67 to 1.03)
0.81 (0.66 to 0.99)
0.82 (0.67 to 1.00)
0.86 (0.74 to 1.00)
0.85 (0.73 to 0.99)
0.87 (0.74 to 1.01)

≥10 min Group
24
22.5 (12.3)
0.74 (0.59 to 0.94
0.77 (0.61 to 0.98)
0.79 (0.62 to 1.01)
0.75 (0.61 to 0.92)
0.79 (0.65 to 0.97)
0.82 (0.67 to 1.00)
0.83 (0.72 to 0.97)
0.85 (0.73 to 0.99)
0.88 (0.75 to 1.02)

Third Tertile
29
205.3 (35.7)
0.88 (0.69 to 1.12)
0.90 (0.71 to 1.15)
0.92 (0.72 to 1.19)
0.78 (0.63 to 0.95)

Model 2
Model 3
Severe sarcopenia
(yes/no)
Model 1
Model 2
Model 3

Ref
Ref

0.93 (0.76 to 1.13)
0.96 (0.78 to 1.17)

0.80 (0.66 to 0.98)
0.82 (0.67 to 1.00)

Ref
Ref
Ref

0.93 (0.80 to 1.08)
0.92 (0.79 to 1.08)
0.94 (0.80 to 1.09)

0.84 (0.72 to 0.97)
0.85 (0.73 to 0.99)
0.87 (0.75 to 1.01)

Dose-response associations of total SB tertiles with sarcopenia status
Total SB (min/day)
First Tertile
Second Tertile
Third Tertile
n
29
29
29
SB, mean (SD)
567.5 (46.0)
651.3 (26.8)
834.2 (135.3)
Probable sarcopenia (yes/no)
Model 1
Ref
0.99 (0.76 to 1.29)
1.20 (0.86 to 1.67)
Model 2
Ref
0.96 (0.73 to 1.25)
1.17 (0.83 to 1.64)
Model 3
Ref
0.91 (0.69 to 1.20)
1.14 (0.80 to 1.61)
Confirmed sarcopenia (yes/no)
Model 1
Ref
1.13 (0.91 to 1.42)
1.47 (1.10 to 1.95)
Model 2
Ref
1.09 (0.88 to 1.35)
1.43 (1.09 to 1.88)
Model 3
Ref
1.06 (0.85 to 1.33)
1.41 (1.06 to 1.86)
Severe sarcopenia (yes/no)
Model 1
Ref
1.15 (0.98 to 1.36)
1.19 (0.97 to 1.47)
Model 2
Ref
1.13 (0.96 to 1.34)
1.18 (0.96 to 1.46)
Model 3
Ref
1.09 (0.92 to 1.30)
1.13 (0.91 to 1.41)
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low
upper limb muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg
for men and <16 kg for women), low muscle mass tested by a dual-energy X-ray absorptiometry
(appendicular skeletal muscle mass: <20 kg for men and <15 kg for women), and low physical
performance assessed by a 20-m usual walking speed test (gait speed: ≤0.8 m/s).
Abbreviations: LIPA: light intensity physical activity; MVPA: moderate to vigorous physical
activity; OR (95% CI): odds ratio (95% confidence interval); Ref: Reference; SB: sedentary
behavior; TAC: Total activity counts.
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular
disease, history of cancer)

Patterns: Table 23 demonstrates the dose-response associations of physical
behavior pattern metrics with sarcopenic status classified by EWGSOP2, including
probable sarcopenia, confirmed sarcopenia, and severe sarcopenia, in the subsample.
Probable sarcopenia: The group of participants with any time spent in long
MVPA bouts (≥10 minutes) had 35% (95% CI 0.47 to 0.89) lower odds for a probable
sarcopenia diagnosis compared to individuals who engaged zero time in long MVPA
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bouts (≥10 minutes) after final adjustment. No significant associations were detected
across tertiles of short MVPA bouts (<10 minutes), sedentary breaks, and ASTP with
probable sarcopenia.
Confirmed sarcopenia: The likelihood for a confirmed sarcopenia diagnosis was
19% (95% CI 0.66 to 0.99, model 2) lower among participants in the highest tertile of
short MVPA bouts (<10 minutes) compared to individuals in the lowest tertile of short
MVPA bouts (<10 minutes). However, significant outcomes of this association were
lacking in model 1 and model 3. There were also significant associations across tertiles of
ASTP with confirmed sarcopenia in model 1 (second tertile: OR=1.24 95% CI 1.01 to
1.52; third tertile: OR: 1.27 95% CI 1.03 to 1.57), but further adjustments for lifestyle
factors (model 2) and chronic health conditions (model 3) attenuated the associations.
There were no significant associations across tertiles of long MVPA bouts (≥10 minutes)
and sedentary breaks with confirmed sarcopenia.
Severe sarcopenia: Participants among the highest tertile of short MVPA bouts
(<10 minutes) had 18% (95% CI 0.71 to 0.96) lower odds of severe sarcopenia compared
to participants in the lowest tertile of short MVPA bouts (<10 minutes) after full
adjustment. Furthermore, individuals in the highest tertile of ASTP demonstrated a 1.23
(95% 1.06 to 1.44, model 2) times higher likelihood for severe sarcopenia compared to
participants in the lowest tertile of ASTP. The significance of this relationship, however,
disappeared after the adjustment for chronic health conditions (model 3). There were no
significant associations across tertiles of long MVPA bouts (≥10 minutes) and sedentary
breaks with severe sarcopenia.
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Table 23: Dose-response associations of patterns of physical behavior metrics with
sarcopenia status
Dose-response associations of short MVPA bouts (<10 minutes) duration tertiles with sarcopenia status
MVPA <10 minute bout (min/day)
First Tertile
Second Tertile
Third Tertile
n
30
28
29
MVPA <10 minute bout, mean (SD)
2.3 (0.7)
5.0 (1.3)
16.9 (10.2)
Probable sarcopenia (yes/no)
Model 1
Ref
0.91 (0.71 to 1.17)
0.80 (0.62 to 1.03)
Model 2
Ref
0.89 (0.69 to 1.14)
0.80 (0.62 to 1.02)
Model 3
Ref
0.90 (0.70 to 1.16)
0.81 (0.63 to 1.05)
Confirmed sarcopenia (yes/no)
Model 1
Ref
1.01 (0.81 to 1.25)
0.81 (0.65 to 1.00)
Model 2
Ref
0.97 (0.79 to 1.19)
0.81 (0.66 to 0.99)
Model 3
Ref
0.98 (0.80 to 1.21)
0.82 (0.67 to 1.01)
Severe sarcopenia (yes/no)
Model 1
Ref
0.92 (0.79 to 1.07)
0.81 (0.69 to 0.95)
Model 2
Ref
0.90 (0.77 to 1.05)
0.81 (0.69 to 0.94)
Model 3
Ref
0.92 (0.79 to 1.08)
0.82 (0.71 to 0.96)
Dose-response associations of long MVPA bouts (≥10 minutes) duration groups with sarcopenia status
MVPA ≥10 minute bout (min/day)
No ≥10 minute bouts
≥10 minute bouts
n
76
11
MVPA ≥10 minute bout, mean (SD)
0.0 (0.0)
8.8 (6.7)
Probable sarcopenia (yes/no)
Model 1
Ref
0.63 (0.47 to 0.85)
Model 2
Ref
0.65 (0.49 to 0.87)
Model 3
Ref
0.65 (0.47 to 0.89)
Confirmed sarcopenia (yes/no)
Model 1
Ref
0.77 (0.59 to 1.00)
Model 2
Ref
0.81 (0.63 to 1.04)
Model 3
Ref
0.87 (0.67 to 1.14)
Severe sarcopenia (yes/no)
Model 1
Ref
0.90 (0.74 to 1.09)
Model 2
Ref
0.02 (0.76 to 1.11)
Model 3
Ref
0.93 (0.76 to 1.14)
Dose-response associations of number of sedentary breaks tertiles with sarcopenia status
Number of sedentary breaks (no. of breaks/day)
First Tertile
Second Tertile
Third Tertile
n
29
29
29
Sedentary breaks, mean (SD)
51.8 (12.7)
71.6 (3.5)
87.8 (6.6)
Probable sarcopenia (yes/no)
Model 1
Ref
1.04 (0.81 to 1.33)
0.90 (0.70 to 1.15)
Model 2
Ref
1.04 (0.81 to 1.34)
0.92 (0.72 to 1.18)
Model 3
Ref
1.06 (0.82 to 1.36)
0.94 (0.72 to 1.23)
Confirmed sarcopenia (yes/no)
Model 1
Ref
1.03 (0.83 to 1.27)
0.81 (0.65 to 1.00)
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Model 2
Model 3
Severe sarcopenia (yes/no)
Model 1
Model 2
Model 3

Ref
Ref

1.03 (0.84 to 1.26)
1.06 (0.87 to 1.29)

0.82 (0.67 to 1.01)
0.82 (0.67 to 1.02)

Ref
Ref
Ref

0.96 (0.82 to 1.13)
0.96 (0.82 to 1.13)
0.97 (0.83 to 1.14)

0.90 (0.77 to 1.05)
0.91 (0.77 to 1.07)
0.94 (0.79 to 1.11)

Dose-response associations of ASTP tertiles with sarcopenia status
First Tertile
29
0.37 (0.05)

ASTP
Second Tertile
29
0.48 (0.03)

Third Tertile
n
29
ASTP, mean (SD)
0.61 (0.08)
Probable sarcopenia (yes/no)
Model 1
Ref
1.23 (0.97 to 1.57)
1.16 (0.91 to 1.48)
Model 2
Ref
1.21 (0.95 to 1.54)
1.12 (0.88 to 1.43)
Model 3
Ref
1.19 (0.93 to 1.53)
1.04 (0.79 to 1.37)
Confirmed sarcopenia (yes/no)
Model 1
Ref
1.24 (1.01 to 1.52)
1.27 (1.03 to 1.57)
Model 2
Ref
1.20 (0.98 to 1.46)
1.20 (0.98 to 1.48)
Model 3
Ref
1.17 (0.96 to 1.44)
1.11 (0.89 to 1.39)
Severe sarcopenia (yes/no)
Model 1
Ref
1.08 (0.93 to 1.25)
1.26 (1.08 to 1.26)
Model 2
Ref
1.07 (0.92 to 1.24)
1.23 (1.06 to 1.44)
Model 3
Ref
1.06 (0.91 to 1.23)
1.18 (1.00 to 1.40)
Notes: Bold values are significant. Probable or confirmed sarcopenia will be defined using low upper limb
muscle strength evaluated by a calibrated handgrip dynamometer (grip strength: <27 kg for men and <16 kg
for women), low muscle mass tested by a dual-energy X-ray absorptiometry (appendicular skeletal muscle
mass: <20 kg for men and <15 kg for women), and low physical performance assessed by a 20-m usual
walking speed test (gait speed: ≤0.8 m/s). The active-to-sedentary transition probability index is calculated by
dividing the total number of breaks in sedentary behavior with the sum of minutes spent in physical activity.
Abbreviations: ASTP: active-to-sedentary transition probability; MVPA: moderate to vigorous physical
activity; OR (95% CI): odds ratio (95% confidence interval).
Model 1: adjusted for age, gender, race, education, accelerometer wear time
Model 2: model 1 + lifestyle factors (BMI, smoking status)
Model 3: model 2 + chronic health conditions (diabetes, hypertension, history of cardiovascular disease,
history of cancer)
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CHAPTER 5
DISCUSSION
The aim of this study was to gain a better understanding regarding the
associations of various accelerometer-determined physical behavior metrics with
sarcopenia status and its components among oldest-old adults. Cross-sectional data from
the Health ABC cohort study of community-dwelling oldest-old adults with a mean age
of 88.2 (2.5) years helps address our research aims. As described in Chapter 3, we created
two different samples for this secondary analysis. The primary sample with a total of 145
participants focused on the associations of physical behavior metrics with EWGSOP2
defined probable sarcopenia and handgrip strength. Moreover, the subsample with 87
participants looked at the associations of physical behavior metrics with EWGSOP2
defined probable, confirmed, and severe sarcopenia as well as their related components
including handgrip strength, appendicular lean mass, and gait speed. The findings of this
study correspond with our hypotheses by highlighting that higher volumes of MVPA,
regardless of its accumulation in short MVPA bouts (<10 minutes) or long MVPA bouts
(≥10 minutes), are associated with lower odds of EWGSOP2 defined sarcopenia and
better sarcopenia-relevant indicators among oldest-old adults.

5.1 Associations of Physical Behavior Volume Metrics with Sarcopenia
The first main subject of discussion represents the interpretation of our study
findings regarding the associations of physical behavior volume metrics, including total
activity counts, total MVPA, total LIPA, and total SB, with sarcopenia and its
components in due consideration of previous research.
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First, there were no significant associations of total activity counts with probable,
confirmed, or severe sarcopenia in our study. These results are not in line with prior
examinations which demonstrated that objectively measured total activity counts are
related with sarcopenia and its components.64,90 Westbury et al.90 and Sanchez-Sanchez et
al.64 observed that higher total activity counts were associated with lower odds of
EWGSOP defined sarcopenia and FNIH defined sarcopenia, respectively. The variety of
used sarcopenic definitions among previous analyses hinders the comparability of
provided study outcomes.20,21 In this context, dissimilarities exist between the original
EWGSOP definition and the revised EWGSOP2 definition in terms of their different cutoff values.22 For instance, while EWGSOP identifies low handgrip strength as <30 kg for
men and <20 kg for women, the EWGSOP2 algorithm diagnoses low handgrip strength
with cut-off points of <27 kg for men and <16 kg for women which leads to considerable
dissimilarities regarding the sarcopenia prevalence rates.131
Furthermore, our study outcomes indicate that accelerometer-determined MVPA
was significantly associated with a lower likelihood of sarcopenia which is in agreement
with previous research.64,66 In this regard, each 5 minutes more per day of MVPA was
related with 27% lower odds for a probable sarcopenic condition among oldest-old
adults. Despite non-significant associations of total MVPA volumes with sarcopenic
conditions in the subsample, we observed a trend that each 5 minutes more per day in
MVPA was related with lower odds of probable and confirmed sarcopenia. The
attenuated significance in the subsample might be caused by the reduced sample size and
the related loss of statistical power. Non-significant findings regarding the associations of
accelerometer-assessed MVPA with sarcopenia are not uncommon. For instance, studies
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from Aggio et al.96 and Westbury et al.90 were also not able to identify any significant
association between objectively measured MVPA and EWGSOP defined sarcopenia.
Likewise, results of the dose-response analysis indicated that the daily volume of MVPA
should exceed 10 minutes in order to significantly lower the odds of probable sarcopenia.
These findings suggest that engaging more time in MVPA may be associated with lower
odds of sarcopenia among oldest-old adults.
A non-significant relationship between LIPA and probable sarcopenia was
illustrated among our primary sample. However, after applying the full EWGSOP2
algorithm to determine the diagnostic state of sarcopenia,18 there were associations with
the likelihood of confirmed and severe sarcopenia. Participants who engaged more time
in LIPA had 18% and 13% lower odds of confirmed and severe sarcopenia, respectively.
In this context, a recent randomized controlled trial study with 28 older women reported
that 8 weeks of SB displacement with LIPA (45-50 minutes daily) significantly improved
handgrip strength and gait speed.132 This is a promising finding since LIPA can be better
sustained than MVPA by older adults.132 Consequently, LIPA might be an encouraging
concept for future health guidelines to improve or maintain musculoskeletal health
among oldest-old adults.
Several studies have reported that accelerometer-determined SB levels are not
related with the prevalence of sarcopenia among older adults.66,96,115 In our sample of
oldest-old adults, spending 60 minutes more per day in SB was associated with a 2.10and 3.79-times higher likelihood for confirmed sarcopenia and severe sarcopenia. More
research is needed to clarify the influence of SB on musculoskeletal health in oldest-old
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adults which might contribute crucial information for future health guidelines.111 Overall,
high levels of SB may be associated with lower odds of confirmed and severe sarcopenia.
With the focus on sarcopenic components, our study outcomes are in agreement
with previous research, showing that higher total activity counts,64,90 higher MVPA,64,96
and higher LIPA96 were associated with better gait speed. On the other hand, higher SB
was associated with worse gait speed which is also in line with prior studies.91,96
Modifications of physical behavior volume metrics by spending more time in active and
less time in sedentary behavior might help enhance the physical performance of oldestold adults. These performance improvements may provide a vital contribution for better
muscle health which is a key factor for independence and thus a higher quality of life
among the oldest-old adult population.133,134

5.2 Associations of Physical Behavior Pattern Metrics with Sarcopenia
The second main subject of discussion represents the interpretation of our study
findings regarding the associations of physical behavior pattern metrics, including short
MVPA bout duration (<10 minutes), long MVPA bout duration (≥10 minutes), total
number of sedentary breaks, and ASTP, with sarcopenia and its components in due
consideration of prior examinations.
Recent studies have shown that the accumulation of MVPA levels with short
bouts of less than 10 minutes contribute to the improvement of various health-related
outcomes.62,63 To the best of our knowledge, this is the first study to look at the
association of accelerometer-determined short MVPA bouts with sarcopenia status and its
components. Interestingly, our study outcomes indicated that higher accumulated time
spent in short MVPA bouts was associated with lower odds of any sarcopenic condition,
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including probable, confirmed, and severe sarcopenia. In this context, Hrubeniuk et al.135
reported that each minute spent in MVPA led to significantly better physical function
among older adults. These findings underscore the potentially positive impact of short
MVPA bouts on sarcopenic status among oldest-old adults. Encouraging oldest-old adults
to accumulate high levels of MVPA without the need to sustain bouts lasting longer than
10 minutes might be beneficially associated with muscle-related health.
Study results from Scott et al.66 indicated that the accumulated time spent in
MVPA bouts longer than 10 minutes was significantly associated with a lower likelihood
of probable or confirmed sarcopenia.66 This is congruent with the outcomes provided in
our primary sample since each 5 minutes more time engaged in long MVPA bouts
indicated 69% lower odds for a probable sarcopenic state. Findings of the dose-response
analysis exhibited that participants who spent at least some time in long MVPA bouts had
a lower likelihood for a probable sarcopenic condition compared to individuals who
engaged zero minutes in long MVPA bouts. However, only a small fraction of people at
this age might be able to engage in long MVPA bouts. Just 21(14.5%) participants in the
primary sample and a total of 11 (12.6%) participants in the subsample provided at least
some minutes in MVPA bouts lasting longer than 10 minutes. A low frequency of long
MVPA bouts was expected due to the advanced age of included individuals.
Unfortunately, the absence of a normal distribution and the high number of participants
with zero minutes spent in long MVPA bouts resulted in a limited ability to statistically
compute binomial logistic regressions in the subsample. This also restricts our capability
to directly compare shorter vs. longer bouts of MVPA in this sample, since so few
individuals accumulated MVPA in longer bouts. Recent evidence reported that older
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adults prefer to participate in short MVPA bouts compared to long MVPA bouts which
might indicate an increased tolerance to accumulate high levels of MVPA minutes via
short sporadic bouts.135 In addition, Menai et al. (2017) reported that higher time spent in
short MVPA bouts was similarly associated with successful aging (defined as a
combination of better cognitive, motor, and respiratory functions as well as absence of
major chronic diseases) as when MVPA was accumulated in prolonged bouts among
older adults. Consequently, short MVPA bouts might be a feasible and efficient
alternative to maintain or improve muscle health among oldest-old adults.
We did not find any significant association of sedentary breaks with probable,
confirmed, or severe sarcopenia. Prior investigations have also indicated no relationship
between the total number of objectively measured sedentary breaks and sarcopenia.96,115
Interestingly, higher numbers of daily sedentary breaks were associated with higher
appendicular lean mass which is not in accordance with the results from Aggio et al.96
who found no association. Frequent interruptions of SB might lead to a multitude of
additional contractions throughout the day which in turn may cause alterations in the
muscle expression of genes responsible for cellular development, growth and
proliferation, and carbohydrate metabolism.136,137 This physiological process might
benefit the musculoskeletal health among older adults. However, epidemiological
research has provided inconclusive evidence with respect to the relationship between
sedentary breaks and muscle mass.111
The analysis of the activity fragmentation in older adults via the active-tosedentary transition probability (ASTP) index is a promising concept for quantifying
patterns of activity, particularly in aging populations.48 As we age, we might expect a
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dramatic change of activity profiles due to functional declines.48 In this context, PA
patterns frequently become more fragmented among older adults due to emerging
difficulties in sustaining PA bouts for a longer period of time.50 Fragmented daily PA
patterns, characterized by a higher ASTP index, have been linked with various
detrimental health outcomes including poor physical performance,48 greater fatigability,50
cognitive impairment,51 and a higher mortality risk in the older adult population.49 This is
the first study we are aware of to identify the association of accelerometer-determined
ASTP with sarcopenia status and its components. Outcomes of the subsample
demonstrated that each 0.1 higher ASTP was linked with 2.90 times greater odds for a
severe sarcopenia diagnosis. Focusing on individual components of sarcopenia, higher
ASTP showed an association with lower gait speed in both genders. Similar findings
were reported by Schrack et al.48, where higher ASTP was also related with worse gait
speed performance among older adults. Therefore, oldest-old adults with less fragmented
activity patterns might demonstrate associations with a lower likelihood of severe
sarcopenia and better gait speed. Comparable outcomes were provided by Chastin et
al.138, who showed a significant relationship between less fragmented activity patterns
and better muscle quality among older adults. In this context, the ASTP index might be a
useful marker for the assessment of accelerated biological aging51 and thus a predictor for
the onset and/or severity of sarcopenia. ASTP does not address differences in total
volume of PA. For instance, an individual who obtains 100 minutes of activity with 10
breaks would provide the same ASTP score as an individual who obtains 10 minutes of
activity with 1 break (ASTP = 0.1 for both). Therefore, ASTP may better represent
physical function than levels of PA. Activity fragmentation in which older adults need to
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break up activity more often might be an early sign for poorer physical function.
Furthermore, we should note that the utilization of activity fragmentation calculations
may be most applicable in old adult populations rather than young adult populations due
to the presence of functional declines with advancing age.48 Consequently, accelerometer
determined activity fragmentation metrics such as the ASTP index might serve as a
valuable indicator of functional declines among older adults.

5.3 Strengths and Limitations
This study benefits from a comprehensive data set among a sample of the oldestold adult population which includes measures of demographic and lifestyle factors,
chronic health conditions, muscle strength, muscle mass, physical performance, and
accelerometry. Owing to the availability of ActiGraph GT3X+ accelerometer data, we
were able to analyze the association of various physical behavior metrics with
EWGSOP2 defined sarcopenia and its determinants. This approach allowed us the
investigation of relationships with clinically relevant sarcopenia definitions as well as the
underlying factors of handgrip strength, appendicular lean mass, and gait speed. Tri-axial
accelerometry is considered a relatively valid and reliable method of evaluating freeliving behavior which provides a detailed estimation of activities in terms of their volume
and intensity.58 Accelerometer data are provided by a demographically diverse
community-dwelling population with a high mean age of 88.2 (2.5) years. Another
strength of our study is the employment of the EWGSOP2 sarcopenia definition which is
widely accepted and endorsed by a range of international scientific societies.18 Moreover,
we utilized DXA-scan data in order to assess muscle mass in our sample. DXA provides
more accurate and reliable estimations of muscle mass compared to other evaluation
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methods such as anthropometric measures or BIA.18 We also created 3 different models
with the purpose to adjust for several key covariates including various demographic
factors plus accelerometer wear time (model 1), lifestyle factors (model 2), and chronic
health conditions (model 3). All these covariates have shown connections with sarcopenic
conditions and their components. In addition, this study provided novel insights into the
associations of short MVPA bouts (<10 minutes) and ASTP with EWGSOP2 defined
sarcopenia and its components.
Our analysis has several limitations. Due to the cross-sectional study design, we
cannot infer causalities regarding the associations of physical behavior metrics with
sarcopenic conditions and their determinants. Despite our hypothesis that higher levels of
intense PA levels are associated with lower sarcopenia-relevant indicators, there is also
the possibility of a reverse causality in which diminished muscle strength, muscle mass,
or physical performance induce lower volumes and intensities of PA. In addition, we had
to remove all Pittsburgh-dwelling individuals from our subsample because of the
unavailability of DXA-scan data. Removing those participants considerably reduced the
statistical power of our subsample analysis. Furthermore, there was a low number of
oldest-old adults with long MVPA bouts which limited our ability to investigate
associations of long MVPA bouts with sarcopenia and its components. Although we
adjusted for a variety of covariates, there remains a possibility of residual confounding.
For example, potential covariates such as malnutrition or osteoporosis were not collected
at year 16 and therefore not included in our study. Unfortunately, despite being the most
rapidly increasing population,7 specified accelerometer cut-off points to determine PA
intensities among oldest-old adults are not available in the current literature. The absence
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of an accelerometer-specific standardized protocol for the oldest-old adult population is
considered a substantial limitation since physical function decreases at an annual rate of
approximately 4% after the age of 65 years.139 Due to age-related physical declines and
related alterations of walking patterns, an oldest-old adult at the age of 85 years might
show a higher energy expenditure for the same activity compared to an older adult at the
age of 65 years.140 Consequently, a lower cut-point for MVPA than that provided by
Copeland et al.130 may be appropriate for oldest-old adults in order to obtain more
accurate evaluations of their physical behavior metrics. We should also note that the
limited ability of ActiGraphs to distinguish between LIPA and SB might lead to a
misclassification of behavioral activities.141,142 In this context, standing activities such as
washing dishes or folding laundry are often disregarded by accelerometers.141,142 Hipworn ActiGraphs also present difficulties in capturing data of upper body movements
which have demonstrated strong associations with sarcopenia and its components.35,142,143
Furthermore, because participants were instructed to remove the accelerometers during
water-related activities, data of muscle-health-promoting aquatic exercises were also
disregarded in our study.144 Nevertheless, missing information about these activities may
not pose a major limitation for our analysis since previous research has shown that the
vast majority of older adults prefer to spend most of their active time in ambulatory
activities such as walking which can be estimated with a relatively high accuracy by hipworn accelerometers.142,145,146
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CHAPTER 6
CONCLUSION
Modifiable characteristics of physical behavior offer promising opportunities to
maintain or improve the musculoskeletal health in oldest-old adults. Our study findings
contribute valuable knowledge to geriatric research by identifying cross-sectional
associations of accelerometer-determined various physical behavior metrics with
EWGSOP2 defined sarcopenia and its components among the oldest-old adult
population. Higher volumes of MVPA, regardless of its pattern of accumulation,
demonstrated associations with lower odds of probable sarcopenia in our primary sample.
Consequently, accruing MVPA in long bouts might not be necessary to lower the
likelihood of a probable sarcopenia diagnosis. This is an important finding for an
increasingly aging population which seems to have difficulties sustaining prolonged
MVPA bouts of at least 10 minutes.
Following the application of the full EWGSOP2 definition in the subsample,
higher volumes of LIPA demonstrated associations with a lower likelihood of confirmed
and severe sarcopenia. Additionally, greater odds of confirmed and severe sarcopenia
were related with higher volumes of SB. This study also observed novel evidence that
higher fragmented activity patterns were associated with severe sarcopenia and lower gait
speed, indicating that activity fragmentation assessments might serve as a valuable index
to detect severely deteriorated musculoskeletal health among the oldest-old adult
population. The results of the dose-response analyses illustrated that most physical
behavior metrics show significant associations with sarcopenic status in the highest tertile
or group, while almost no significant links were seen among the second tertile or group.
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This may provide the opportunity to define specific doses of daily physical behavior
which might help lower the odds of sarcopenia in the oldest-old adult population. With
focus on individual components of EWGSOP2 defined sarcopenia, our findings suggest
that especially higher levels of PA, including total activity counts, MVPA, and LIPA,
were associated with better gait speed. Therefore, physical function among oldest-old
adults might be better preserved when overall greater volumes of PA are realized.
Based on the findings of our study, we can conclude that patterns of accumulated
MVPA had an equally strong association with sarcopenia as the total volume of MVPA,
highlighting the fact that short sporadic MVPA bouts might help maintain or improve
musculoskeletal health in oldest-old adults. Overall, short MVPA bouts should gain more
attention in geriatric research since they may provide information that can help design
feasible and muscle-health promoting PA recommendations for the oldest-old adult
population.
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